WO2010068253A1 - Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates - Google Patents

Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates Download PDF

Info

Publication number
WO2010068253A1
WO2010068253A1 PCT/US2009/006422 US2009006422W WO2010068253A1 WO 2010068253 A1 WO2010068253 A1 WO 2010068253A1 US 2009006422 W US2009006422 W US 2009006422W WO 2010068253 A1 WO2010068253 A1 WO 2010068253A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
crystal form
mixture
added
Prior art date
Application number
PCT/US2009/006422
Other languages
French (fr)
Inventor
Hiroshi Yoshida
Yoshiyuki Taoda
Brian Alvin Johns
Original Assignee
Shionogi & Co., Ltd.
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010068253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MX2011006241A priority Critical patent/MX2011006241A/en
Priority to US13/128,992 priority patent/US8624023B2/en
Priority to CN200980149697.6A priority patent/CN102245182B/en
Priority to JP2011540689A priority patent/JP5086478B2/en
Priority to BRPI0923217A priority patent/BRPI0923217A2/en
Priority to EP09832226.6A priority patent/EP2376080B1/en
Priority to RU2011121785/04A priority patent/RU2527451C2/en
Priority to ES09832226.6T priority patent/ES2641765T3/en
Priority to KR1020177008482A priority patent/KR101847887B1/en
Priority to KR1020117016066A priority patent/KR101733625B1/en
Priority to CA2744019A priority patent/CA2744019C/en
Priority to SG2011035102A priority patent/SG171308A1/en
Priority to AU2009325128A priority patent/AU2009325128B2/en
Priority to MX2013008013A priority patent/MX351942B/en
Application filed by Shionogi & Co., Ltd., Glaxosmithkline Llc filed Critical Shionogi & Co., Ltd.
Publication of WO2010068253A1 publication Critical patent/WO2010068253A1/en
Priority to US14/096,191 priority patent/US8754214B2/en
Priority to US14/272,823 priority patent/US9242986B2/en
Priority to AU2014277831A priority patent/AU2014277831C1/en
Priority to US14/936,987 priority patent/US9365587B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention comprises modifications of known processes for synthesizing compounds having HIV integrase inhibitory activity. .
  • WO 2006/116764 published 2 November 2006, incorporated by reference in its entirety, describes various compounds and detailed synthetic schemes for their preparation.
  • a reaction sequence is depicted at page 79 thereof wherein 3-benzyloxy-2- methyl-1 H-pyridine-4-one of formula 3 is there brominated to the bromopyridine 4 there, which is then reacted with methanol and carbon monoxide to yield the nicotinic acid methyl ester 5 there which is after several steps reacted with a benzylamine to create the amide side chain-containing pyridine 10.
  • the amide sidechain is in place before creation of the Z 1 Z 2 ring of the final product formula (I) therein in the reaction depicted at page 80 from 16 to 17-1.
  • a second reaction sequence is depicted at page 113 of WO 2006/116764 wherein a pyrrolidine compound 102 is allowed to condense into a tricyclic compound 103 which is then brominated to yield the bromine compound 104 which is then reacted with a benzylamine to create the amide side chain-containing tricyclic compound 105 therein.
  • the bromination takes place after creation of the Z 1 Z 2 ring of the final product of formula (I) therein.
  • N-Methoxy-N-methyl amides may be prepared by Pd catalyzed aminocarbonylation of aryl bromides as described by J. R. Martinelli et al in Organic Letters, Vol. 8, No.21 , pages 4843-4846 (2006). Bromoanilines and bromoanisoles are converted to esters as described by J. Albaneze-Walker et al in Organic Letters, Vol. 6, No.13, pages 2097-2100 (2004). Summary of the Invention
  • the bromination provides the leaving group for attachment of an amide side chain on a pyridone ring.
  • a process is provided within a synthesis of a pyridone compound of the following formula (AA), (BB) or (CC):
  • R is -CHO 1 -CH(OH) 2 , -CH(OH)(OR 4 ), -CH(OH)-CH 2 OH or -CH(OR 5 KOR 6 );
  • P 1 is H or a hydroxyl protecting group
  • P 3 is H or a carboxy protecting group
  • R 4 is lower alkyl
  • R 5 and R 6 are independently lower alkyl or R 5 and R 6 can be lower alkyl and joined to form a 5-, 6-, or 7-membered ring,
  • lower alkyl refers to a straight- chain or branched-chain saturated aliphatic hydrocarbon radical containing 1 to 6 carbon atoms.
  • alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, n-hexyl and the like.
  • lower cycloalkyl refers to a saturated or partially saturated carbocyclic ring composed of 3-6 carbons in any chemically stable configuration.
  • suitable carbocyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl.
  • lower alkenyl refers to a straight- chain or branched-chain alkyl group with one or two carbon-carbon double bonds.
  • alkenyl radicals include, but are not limited to, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, hexenyl, hexadienyl and the like.
  • lower alkylene refers to a straight or branched chain divalent hydrocarbon radical, preferably having from one to six carbon atoms, unless otherwise defined.
  • alkylene as used herein include, but are not limited to, methylene, ethylene, propylene, butylene, isobutylene and the like.
  • lower alkenylene refers to a straight or branched chain divalent hydrocarbon radical, one or two carbon-carbon double bonds.
  • lower alkoxy refers to an alkyl ether radical, wherein the term “alkyl” is defined above.
  • suitable alkyl ether radicals include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like.
  • halogen refers fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
  • aryl alone or in combination with any other term, refers to a carbocyclic aromatic moiety (such as phenyl or naphthyl) containing 6 carbon atoms, and more preferably from 6-10 carbon atoms.
  • aryl radicals include, but are not limited to, phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl, indanyl, phenanthridinyl and the like.
  • aryl also includes each possible positional isomer of an aromatic hydrocarbon radical, such as in 1-naphthyl, 2-naphthyl, 5-tetrahydronaphthyl, 6-tetrahydronaphthyl, 1- phenanthridinyl, 2-phenanthridinyl, 3-phenanthridinyl, 4-phenanthridinyl, 7- phenanthridinyl, 8-phenanthridinyl, 9-phenanthridinyl and 10-phenanthridinyl.
  • aryl radicals include, but are not limited to, phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl, indanyl, phenanthridinyl and the like.
  • aralkyl refers to an alkyl group substituted by an aryl. Examples of aralkyl groups include, but are not limited to, benzyl and phenethyl.
  • heterocyclic group refers to a 3- to 7- membered monocyclic heterocyclic ring or 8-to 11- membered bicyclic heterocyclic ring system any ring of which is either saturated, partially saturated or unsaturated, and which may be optionally benzofused if monocyclic.
  • Each heterocycle consists of one or more carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen atom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any carbon or heteroatom, provided that the attachment results in the creation of a stable structure.
  • Preferred heterocycles include 5-7 membered monocyclic heterocycles and 8-10 membered bicyclic heterocycles.
  • substituents it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
  • Heteroaromatics or “heteroaryl” are included within the heterocycles as defined above and generally refers to a heterocycle in which the ring system is an aromatic monocyclic or polycyclic ring radical containing five to twenty carbon atoms, preferably five to ten carbon atoms, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, S and P.
  • Preferred heteroaryl groups include 5-6 membered monocyclic heteroaryls and 8 - 10 membered bicyclic heteroaryls.
  • heterocycle is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl or tetrahydro-quinolinyl, where the radical or point of attachment is on the non-aromatic heteroatom-containing ring.
  • heterocycle, heterocyclic or “heterocyclyl” also included each possible positional isomer of a heterocyclic radical, such as in 1 -indolinyl, 2-indolinyl, 3-indolinyl.
  • heterocycles include imidazolyl, imidazolinoyl, imidazolidinyl, quinolyl, isoquinolyl, indolyl, indazolyl, indazolinolyl, perhydropyridazyl, pyridazyl, pyridyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazinyl, quinoxolyl, piperidinyl, pyranyl, pyrazolinyl, piperazinyl, pyrimidinyl, pyridazinyl, morpholinyl, thiamorpholinyl, furyl, thienyl, triazolyl, thiazolyl, carbolinyl, tetrazolyl, thiazolidinyl, benzofuranoyl, thiamorpholinyl sulfone, oxazolyl, oxadiazol
  • Optional substituents are hydroxy, halogen, amino and lower alkyl.
  • Protecting groups may be selected from groups known to those skilled in the art, including protecting groups disclosed in Greene, Theodora W.; Wuts, Peter G. M.. Protective Groups in Organic Synthesis. 2nd Ed. (1991),473 pp. or Kocienski, Philip J. Protecting Groups. 3rd Ed. 2005, (2005), 679 pp.
  • step P-22) can be carried out before or after creation of the Q ring, such steps for the creation of the Q ring being described herein and in WO 2006/1116764.
  • the present invention features a process as described above, wherein said step P-2) is carried out before creation of the Q ring and wherein said pyridone compound is of the formula AA or formula BB or formula CC.
  • the present invention features a process as described above, wherein said step P-2) is carried out after creation of the Q ring and wherein said pyridone compound is of the formula AA or formula BB or formula CC.
  • the present invention features a process as described above, wherein the pyridone compound is of the formula AA.
  • the present invention features a process as described above, wherein the pyridone compound is of the formula BB.
  • the present invention features a process as described above, wherein the pyridone compound is of the formula CC.
  • a process is provided for the preparation of a pyridone compound of the following formula (AA), (BB) or (CC):
  • R is -CHO, -CH(OH) 2 , -CH(OH)(OR 4 ), -CH(OH)-CH 2 OH or — CH(OR 5 J(OR 6 );
  • P 1 is H or a hydroxyl protecting group;
  • P 3 is H or a carboxy protecting group;
  • R 4 is lower alkyl;
  • R s and R 6 are independently lower alkyl or R 5 and R 6 can be lower alkyl and joined to form a 5-, 6-, or 7-membered ring,
  • the present invention also features processes as described above wherein P 1 is benzyl; P 3 is methyl; and R is -CHO, -CH(OH)(OR 4 ), -CH(OR 5 )(OR 5 ) wherein R 4 and R 5 are lower alkyl.
  • R is -CHO, -CH(OH) 2 or -CH(OH)(OR 4 );
  • P 1 is H or a hydroxyl protecting group;
  • P 3 is H or a carboxy protecting group;
  • R 3 is H, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted lower alkenyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterocyclic group, optionally substituted heterocycleoxy and optionally substituted amino;
  • R 4 is lower alkyl;
  • R x is H, halo or R 2 -X-NR 1 -C(O)-;
  • R 2 is optionally substituted aryl;
  • X is a single bond, a heteroatom group selected from O, S 1 SO, SO 2 , and NH or loweralkylene or lower alkenylene wherein each may be intervened by the heteroatom;
  • R 1 is H or lower alkyl, which comprises the steps of: i) reacting a compound of formula (II):
  • R 5 and R 6 are independently lower alkyl or R 5 and R 6 can be alkyl and joined to form a 5-, 6-, or 7-membered ring,
  • the product (Ia) of a synthetic sequence can be condensed with an amine, eg of the formula H 2 NCI-I 2 CH 2 CH 2 OH, brominated if R x is H 1 carbonylated and amidated and finally, debenzylated to yield a compound of WO 2006/116764 designated (I-7) at page 240 wherein (R) m is 4-F and R a is H.
  • an amine eg of the formula H 2 NCI-I 2 CH 2 CH 2 OH
  • brominated if R x is H 1 carbonylated and amidated and finally, debenzylated to yield a compound of WO 2006/116764 designated (I-7) at page 240 wherein (R) m is 4-F and R a is H.
  • such a compound may be synthesized by starting with (I) where R x is p-F-phenyl-CH 2 -NH-C(O)-, R 3 is H, P 1 is benzyl (Bn)
  • step i) can be carried out out in a protic or aprotic solvent such as EtOH, THF or DMF at a temperature of about 50-150° C for about 1-10 hours.
  • a protic or aprotic solvent such as EtOH, THF or DMF
  • step ii) can be carried out for the diol starting material (Vl) with an oxidizing agent such as NaIO 4 , RuO 4 or Pb(OAc) 4 in a solvent such as H 2 O, MeOH or CH 3 CN at ambient temperature for one or more hours.
  • an oxidizing agent such as NaIO 4 , RuO 4 or Pb(OAc) 4 in a solvent such as H 2 O, MeOH or CH 3 CN at ambient temperature for one or more hours.
  • reaction may be in an acid such as HCI, CF 3 COOH or HCOH optionally with heating.
  • step P-1) can be carried out by treating a compound of formula l-l with a bromine source including but not limited to ⁇ /-bromosuccinimide or bromine in a solvent such as ⁇ /, ⁇ /-dimethyl formamide, THF or acetic acid and the like.
  • a bromine source including but not limited to ⁇ /-bromosuccinimide or bromine in a solvent such as ⁇ /, ⁇ /-dimethyl formamide, THF or acetic acid and the like.
  • This transformation can be run particularly at a temperature of -10 0 C to 50 0 C to produce a compound of formula H-Il.
  • step P-2) can be carried out by treating a compound of formula H-Il with 2,4-difluorophenyl-CH 2 -NH 2l carbon monoxide, a suitable base and palladium (0) source and optionally an appropriate ligand in an inert solvent optionally with heating.
  • the carbon monoxide can be at atmospheric pressure (14.7 psi) or at elevated pressure particularly in the range of up to 60 psi but in some cases higher pressures may be required.
  • Bases include but are not limited to tertiary amine bases such as diisopropylethylamine and triethylamine and the like. Inorganic bases such as potassium acetate and potassium phosphate are also bases of significance.
  • Suitable sources of Pd (0) include but are not limited to tetrakis triphenylphosphine palladium (0).
  • a Pd (II) precursor can be used to generate Pd (0) in situ.
  • Suitable Pd (II) precursors include but are not limited to Pd(OAc) 2 , Pd(OCOCF 3 ) 2 and ligands include Xantphos, diphenylphosphinoferrocene (dppf), triphenylphosphine and the like.
  • Solvents include ⁇ /./v-dimethyl formamide, THF 1 toluene, DMSO and the like. Heating the mixture is optionally used in the range from ambient to 150 0 C
  • the present invention also features crystalline forms of a compound of formula AA (Compound 13, Example 1) salt and a hydrate thereof.
  • the present invention features:
  • the present invention features crystalline forms of a salt of compound of formula AA, in particular a sodium salt.
  • the present invention features crystalline forms of a hydrate of a salt of a compound of formula AA, in particular a sodium salt.
  • This invention also includes a crystal form of a compound of formula AA (Compound 12, Example 1). Details are shown as (17) to (22):
  • a crystal form of a compound of formula AA having characteristic diffraction peaks at 5.4° ⁇ 0.2°, 10.7° ⁇ 0.2°, 12.3° ⁇ 0.2°, 14.3° ⁇ 0.2°, 15.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 21.7° ⁇ 0.2°, 24.9° ⁇ 0.2°, 25.4° ⁇ 0.2° and 27.9° ⁇ 0.2° degrees two-theta in an X-ray powder diffraction pattern.
  • the crystals of compound 13 and 13b demonstrate high solubility in water or saline, high bioavailability (BA), high maximum drug concentration (Cmax), short maximum drug concentration time (Tmax), high stability against heat or light, and/or good handling facility. Therefore, the crystals of compound 13 and 13b are suitable as pharmaceutical ingredients.
  • Example 1e and 3e The starting material of Example 1e and 3e is the compound of formula (Ha) which is also shown as compound 5 below and compound #101 at page 113 of WO 2006/116764.
  • the product depicted below as compound 8 is of the formula (I).
  • the final product shown below as compound 13 is a compound of formula (I-7) at page 240 of WO 2006/116764 wherein (R) n , is 2,4-di-F and R a is H, provided, however, that there is an alpha methyl at the position designated R 16 in formula (XXVI) at page 65.
  • compound 5 is identical to compound 101 at page 113 of WO 2006/116764 and to formula (Ha) of the process of the present invention
  • compound 6 above is identical to formula (Via) of the process of the present invention
  • compound 7 above is identical to formula (VIb) of the process of the present invention
  • compound 8 is identical to formula (Ia) of the process of the present invention.
  • Step i) of the invention process is S to 6 above while step ii) is 6 to 8.
  • Example 1a To a slurry of 2000 g of compound 1(1.0 eq.) in 14.0 L of MeCN were added 2848 g of benzyl bromide(1.05 eq.) and 2630 g of K 2 CO 3 (1.2 eq.). The mixture was stirred at 80 0 C for 5 h and cooled to 13°C. Precipitate was filtered and washed with 5.0 L of MeCN. The filtrate was concentrated and 3.0 L of THF was added to the residue. The THF solution was concentrated to give 3585 g of crude compound 2 as oil. Without further purification, compound 2 was used in the next step.
  • Example 1g To a mixture of 507 g of compound 7(1.0 eq.) in 5.07 L of MeCN, 5.07 L of H 2 O and 9.13 g of AcOH(0.1 eq.) was added 390 g of NaIO 4 (1.2 eq.) and the mixture was stirred at room temperature for 2 h. After addition of 1.52 L of 10% Na 2 S 2 O 3 aq., the mixture was concentrated and cooled to 10 0 C. Filtration, washing with H 2 O and drying provided 386 g of compound 8 (80% yield) as a crystal.
  • Example 1i To a slurry of 332 g of compound 9 (1.0 eq.) in 1.66 L of NMP was added 191 g of
  • Example 1j Under carbon mono-oxide atmosphere, a mixture of 33.5 g of compound 10(1.0 eq.), 34.8 ml_ of /-Pr 2 NEt(2.5 eq.), 14.3 ml_ of 2,4-difluorobenzylamine(1.5 eq.) and 4.62 g of Pd(PPh 3 ) 4 (0.05 eq.) in 335 mL of DMSO was stirred at 90 0 C for 5.5 h. After cooling, precipitate was filtered and washed with 50 mL of 2-propanol.
  • Example 1k Under hydrogen atmosphere, a mixture of 28.0 g of compound 11 (1.0 eq.) and 5.6 g of 10% Pd-C in 252 mL of THF and 28 mL of MeOH was stirred for 1 h. After precipitate (Pd-C) was filtered and washed with 45 mL of THF, 5.6 g of 10% Pd-C was added and the mixture was stirred for 1.5 h under hydrogen atmosphere. After Pd-C was filtered and washed with 150 mL of CHCl3/MeOH(9/1 ), the filtrate was concentrated. After dissolution of the residue in 1.38 L of EtOH by heating, the solution was gradually cooled to room temperature. After filtration, the filtrate was concentrated and cooled.
  • Example 11 After dissolution of 18.0 g of compound 12 (1.0 eq.) in 54 mL of EtOH by heating, followed by filtration, 21.5 mL of 2N NaOHaq.(1.0 eq.) was added to the solution at 80 0 C. The solution was gradually cooled to room temperature. Filtration, washing with 80 mL of EtOH and drying provided 18.8 g of compound 13 (99% yield) as a crystal.
  • Example 1m shows a process for preparation of the crystalline compound 13b which is monohydrate form of compound 13.
  • Example 3b To 904 g of the crude compound 2 was added 5.88 L of THF and the solution was cooled to -60 0 C. 5.00 L of 1.0 M of Lithium bis(trimethylsilylamide) in THF(1.25 eq.) was added dropwise for 2 h to the solution of compound 2 at -60 0 C. Then, a solution of 509 g of benzaldehyde(1.2 eq.) in 800 mL of THF was added at -60 "C and the reaction mixture was aged at -60 0 C for 1 h. The THF solution was poured into a mixture of 1.21 L of conc.HCI, 8.14 L of ice water and 4.52 L of EtOAc at less than 2 0 C.
  • Example 3d To a mixture of 10.0 g of compound 4 and 13.6 mg of RuCI 3 nH 2 O in 95 mL of MeCN and
  • NMP were added 431 g of NaHCO 3 (3.0 eq.) and 160 mL of methyl iodide(1.5 eq.) and the mixture was stirred at room temperature for 4 h. After cooling to 5 0 C, 1.71 L of 2N HCI and 1.15 L of 20% NaClaq were added to the mixture at less than 10 0 C to give crystal of compound 7. Filtration, washing with 1.73 L of H 2 O and drying provided 507 g of compound 7 (89% yield) as a crystal.
  • Apparatus and conditions used to generate Figures 1 - 7 are as follows: Measurement of X-ray Powder Diffraction Pattern The measuring conditions used were the same as general metrology for the X-ray powder diffraction pattern measurement described in "The Japanese Pharmacopoeia Fifteenth Edition".
  • the sample was prepared on an aluminum wafer
  • the acquisition conditions used for were as follows.
  • the spectrum was obtained using the cross polarization magic-angle-spinning (CP/MAS) method.
  • the acquisition conditions were as follows.
  • Example A depicts a process in providing an intermediate for the compound of formula 17 below which is isomeric to the compound ZZ-2 at page 237 of WO 2006/116764 to Brian Johns et al.
  • Example Aa After dissolution of mixture of 320 g of compound 8 (1.0 eq.) in 3.20 L of MeOH by heating, the solution was concentrated. To the residue, 1.66 L of MeCN, 5.72 mL of AcOH(0.1 eq.) and 82.6 g of (S)-2-Amino-propan-1-ol(1.1 eq.) were added and the mixture was heated to 70 °C, stirred at 70 0 C for 4 h and concentrated. To the residue, 1.67 L of 2-propanol was added and the mixture was concentrated (twice). After cooling of the residue, filtration, washing with 500 mL of cold 2-propanol and drying provided 167 g of compound 14 (52% yield) as a crystal.
  • This Example B utilizes a process to insert a ring nitrogen in place of oxygen in a pyrone ring and create an aldehyde equivalent by an osmium oxidation of a double bond.
  • this example is not a bromination of the invention.
  • Example C shows a refunctionalization of a compound 6 as shown above in Example 1 (of formula (Vl)), including a bromination at the R* position, to yield final products 20 and 21 (of formula (I)).
  • Such compounds with Br at the R x position can be reacted as in Examples 1 and 2 to add the R 2 -X-NR 1 -C(O)- sidechain.
  • a reactor was charged with 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4- dihydro-2-pyridinecarboxylic acid 6 (4.302 kg, 13.47 mol) followed by charging with NaHCO 3 (1.69 kg, 20.09 mol) and 242 g of deionized water. To this was added 21.4 kg of NMP and the mixture was stirred and temperature brought to 28-35 0 C. Dimethyl sulfate (2.34 kg, 18.30 mol) was added dropwise via an addition funnel to the reaction mixture over 1-3 hours keeping the temperature at 28-33 0 C. The slurry was agitated at this temperature for 14 h.
  • reaction mixture When deemed complete, the reaction mixture was cooled to 5 0 C or below and the mixture was neutralized to pH 6 by the addition of HCI (561 mL of cone HCI in 2806 g of deionized water).
  • HCI 561 mL of cone HCI in 2806 g of deionized water.
  • the reaction vessel was slowly charged with cold 20% brine solution composed of 8.7 kg NaCI, 20 kg of deionized water and 14.8 kg of ice at a maximum temperature of 10 0 C.
  • the mixture was agitated at 0-10 0 C for 2.5 h.
  • the slurry was filtered under vacuum and the cake washed with 15 kg of deionized water two times.
  • the wet solid product was dried at 45-55 0 C under vacuum until constant weight was obtained.
  • a reactor was charged with (3.759 kg, 11.27 mol) of methyl 1-(2,3-dihydroxypropyl)-4-oxo- 3-[(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylate 7 and 18.8 L of DMF.
  • N-bromosuccinimide 2.220 kg, 12.47 mol
  • the resultant mixture was stirred at rt for 16 h. At this time less than 1% of starting material was present by HPLC.
  • the mixture was worked up in half batches by cooling to 10 0 C and added an ice/water mixture (12 kg ice in 35 kg deionized water) and the mixture was agitated, then filtered. This was repeated for the second half of the batch.
  • the combined filter cake was washed with 14 L of water and dired in a vaccum oven to provide 4.033 kg of methyl 5-bromo-1-(2,3-dihydroxypropyl)-4- oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate 19 (91.6%) as an off-white powder of 99.2% HPLC purity.
  • a reactor was charged with sodium periodate (1.67 kg, 7.8 mol) and 44 L of deionized water. To the agitated mixture was added 8.5 kg of ice. This was stirred until all the ice melted and the mixture temperature was 1.4 0 C. To this was added methyl 5-bromo-1- (2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylate 19 (2.73 kg, 6.62 mol) via a powder addition funnel. The mixture was allowed to warm to rt and the slurry was stirred for 16 h. A sample was monitored by 1 H NMR and showed the disappearance of starting material.
  • This Example shows a reaction of a compound 5 of formula (II) with one of (III) in step i) and a refunctionalization step ii) of compounds of formula (V) (compounds 22, 23, 24 and 25) in producing compounds of formula (I).
  • a pressure vessel was charged with methyl 1-[2,2-bis(methyloxy)ethyl]-5-bromo-4-oxo-3- [(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate 24 (6.4g, 15 mmol), 2,4- difluorobenzylamine (3.2g, 22.5 mmol), K 3 PO 4 (9.45g, 45mmol), Pd(OCOCF 3 J 2 (398mg, 1.2 mmol), Xantophos (694mg, 1.2 mmol) and toluene (200 mL). The mixture was purged by CO (4X) before being heated to 100 0 C for 22 hours under CO atmosphere (60psi).
  • Methyl 1-[2,2-bis(methyloxy)ethyl]-5-( ⁇ [(2,4-difluorophenyl)methyl]amino ⁇ carbonyl)-4-oxo- 3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate 25 (11.6 g ) was treated with 90% formic acid (250 mL) at 40 0 C for -12 hours (monitored by LC-MS). After the solvents were evaporated at ⁇ 40 0 C 1 the residue was re-dissolved in EtOAc ( ⁇ 1 L) and the resulting solution was washed with NaHCO 3 and brine. The organic phase was then dried over Na 2 SO 4 .
  • Example CCa (4aS, 13a/?)-8-Bromo-10-[(phenylmethyl)oxy]-2,3,4a,5, 13,13a-hexahydro- 1 H-pyrido[1 ,2-a]pyrrolo[1 ',2':3,4]imidazo[1 ,2-Gflpyrazine-9, 11 -dione (DD).
  • a reactor was charged with [(2f?)-2-pyrrolidinylmethyl]amine (0.75 kg) and 4.6 L of DMF was added followed by 0.45 kg of glacial acetic acid. Acetonitrile (41.4 L) was then added and the mixture was agitated for 15 minutes.
  • Example CCb (4aS,13aR)- ⁇ /-[(2,4-Difluorophenyl)methyl]-9 l 11-dioxo-10- [(phenylmethyl)oxy]-2,3,4a,5,9,11 ,13,13a-octahydro-1
  • a reaction vessel was charged with (4aS, 13af?)-8-bromo-10-[(phenylmethyl)oxy]-2,3,4a,5, 13, 13a-hexahydro-1 H- pyridoII ⁇ -alpyrroloti'. ⁇ ' ⁇ limidazoli.Z-cdpyrazine- ⁇ .i i-dione (1.4 kg), 2,4- difluorobenzylamine (705 g), Hunigs base (1.4L), dppf (60 g) and DMSO (12 L). The mixture was degassed with high purity nitrogen 4 times. To this mixture was added palladium (II) trifluoroacetate (18 g) in DMSO (2L).
  • Example CCc (4aS,13af?)- ⁇ /-[(2,4-Difluorophenyl)methyl]-10-hydroxy-9,11-dioxo- 2,3,4a,5,9, 11,13,13a-octahydro-1 H-pyrido[1 ,2-a]pyrrolo[1 l ,2 I :3,4]imidazo[1 ,2-d]pyrazine-8- carboxamide.
  • a pressure reaction vessel was charged with (4aS,13af?)- ⁇ /-[(2,4- Difluorophenyl)methyl]-9, 11 -dioxo-10-[(phenylmethyl)oxy]-2,3,4a,5,9, 11 , 13, 13a- octahydro-1 H-pyrido[1 ,2-a]pyrrolo[1 ',2':3,4]imidazo[1 ,2-c/]pyrazine-8-carboxamide (950 g), 192 g of palladium on carbon (50% wet), ethanol (9.5 L) and concentrated ammonium hydroxide (124 mL).
  • the mixture was degassed with nitrogen 3 times and then placed under 50 psi of hydrogen until the reaction was complete.
  • the mixture was degassed again with nitrogen and then filtered through Celite.
  • the cake was extracted with refluxing dichloromethane and then filtered again.
  • the combined filtrates were concentrated to a small volume (4L), azeotroped with ethanol (28.5L) to a final volume of 9 L.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A synthesis approach providing an early ring attachment via a bromination to compound l-l yielding compound II-Il, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.

Description

SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND
INTERMEDIATES
Field of the Invention
The present invention comprises modifications of known processes for synthesizing compounds having HIV integrase inhibitory activity. .
Background of the Invention
WO 2006/116764 published 2 November 2006, incorporated by reference in its entirety, describes various compounds and detailed synthetic schemes for their preparation. In particular, a reaction sequence is depicted at page 79 thereof wherein 3-benzyloxy-2- methyl-1 H-pyridine-4-one of formula 3 is there brominated to the bromopyridine 4 there, which is then reacted with methanol and carbon monoxide to yield the nicotinic acid methyl ester 5 there which is after several steps reacted with a benzylamine to create the amide side chain-containing pyridine 10. Thus, the amide sidechain is in place before creation of the Z1Z2 ring of the final product formula (I) therein in the reaction depicted at page 80 from 16 to 17-1.
A second reaction sequence is depicted at page 113 of WO 2006/116764 wherein a pyrrolidine compound 102 is allowed to condense into a tricyclic compound 103 which is then brominated to yield the bromine compound 104 which is then reacted with a benzylamine to create the amide side chain-containing tricyclic compound 105 therein. Thus, the bromination takes place after creation of the Z1Z2 ring of the final product of formula (I) therein.
N-Methoxy-N-methyl amides may be prepared by Pd catalyzed aminocarbonylation of aryl bromides as described by J. R. Martinelli et al in Organic Letters, Vol. 8, No.21 , pages 4843-4846 (2006). Bromoanilines and bromoanisoles are converted to esters as described by J. Albaneze-Walker et al in Organic Letters, Vol. 6, No.13, pages 2097-2100 (2004). Summary of the Invention
Processes are provided which utilize an early bromination step in the construction of compounds useful as having HIV integrase inhibitory activity as set forth in WO
2006/116764. The bromination provides the leaving group for attachment of an amide side chain on a pyridone ring.
Detailed Description of the Invention
A process is provided within a synthesis of a pyridone compound of the following formula (AA), (BB) or (CC):
Figure imgf000004_0001
Figure imgf000004_0002
Figure imgf000004_0003
comprising the steps of:
P-1) brominating a compound of the following formula (l-l) to produce a bromine compound of the following formula (H-Il):
Figure imgf000005_0001
l-l H-H
wherein
R is -CHO1 -CH(OH)2, -CH(OH)(OR4), -CH(OH)-CH2OH or -CH(OR5KOR6);
P1 is H or a hydroxyl protecting group; P3 is H or a carboxy protecting group; R4 is lower alkyl;
R5 and R6 are independently lower alkyl or R5 and R6 can be lower alkyl and joined to form a 5-, 6-, or 7-membered ring,
and
P-2) creating the 2,4-di-fluorophenyl-CH2-NH-C(O)- sidechain with the reactants 2,4-di-fluorophenyl-CH2-NH2 and carbon monoxide.
The term "lower alkyl", alone or in combination with any other term, refers to a straight- chain or branched-chain saturated aliphatic hydrocarbon radical containing 1 to 6 carbon atoms. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, n-hexyl and the like.
The term "lower cycloalkyl" refers to a saturated or partially saturated carbocyclic ring composed of 3-6 carbons in any chemically stable configuration. Examples of suitable carbocyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl.
The term "lower alkenyl," alone or in combination with any other term, refers to a straight- chain or branched-chain alkyl group with one or two carbon-carbon double bonds. Examples of alkenyl radicals include, but are not limited to, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, hexenyl, hexadienyl and the like. The term "lower alkylene" refers to a straight or branched chain divalent hydrocarbon radical, preferably having from one to six carbon atoms, unless otherwise defined. Examples of "alkylene" as used herein include, but are not limited to, methylene, ethylene, propylene, butylene, isobutylene and the like.
The term "lower alkenylene" refers to a straight or branched chain divalent hydrocarbon radical, one or two carbon-carbon double bonds.
The term "lower alkoxy" refers to an alkyl ether radical, wherein the term "alkyl" is defined above. Examples of suitable alkyl ether radicals include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like.
The term "halogen" refers fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
The term "aryl" alone or in combination with any other term, refers to a carbocyclic aromatic moiety (such as phenyl or naphthyl) containing 6 carbon atoms, and more preferably from 6-10 carbon atoms. Examples of aryl radicals include, but are not limited to, phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl, indanyl, phenanthridinyl and the like. Unless otherwise indicated, the term "aryl" also includes each possible positional isomer of an aromatic hydrocarbon radical, such as in 1-naphthyl, 2-naphthyl, 5-tetrahydronaphthyl, 6-tetrahydronaphthyl, 1- phenanthridinyl, 2-phenanthridinyl, 3-phenanthridinyl, 4-phenanthridinyl, 7- phenanthridinyl, 8-phenanthridinyl, 9-phenanthridinyl and 10-phenanthridinyl. Examples of aryl radicals include, but are not limited to, phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl, indanyl, phenanthridinyl and the like. The term "aralkyl" refers to an alkyl group substituted by an aryl. Examples of aralkyl groups include, but are not limited to, benzyl and phenethyl.
The term "heterocyclic group," and "heterocycle" as used herein, refer to a 3- to 7- membered monocyclic heterocyclic ring or 8-to 11- membered bicyclic heterocyclic ring system any ring of which is either saturated, partially saturated or unsaturated, and which may be optionally benzofused if monocyclic. Each heterocycle consists of one or more carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen atom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any carbon or heteroatom, provided that the attachment results in the creation of a stable structure. Preferred heterocycles include 5-7 membered monocyclic heterocycles and 8-10 membered bicyclic heterocycles. When the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results. "Heteroaromatics" or "heteroaryl" are included within the heterocycles as defined above and generally refers to a heterocycle in which the ring system is an aromatic monocyclic or polycyclic ring radical containing five to twenty carbon atoms, preferably five to ten carbon atoms, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, S and P. Preferred heteroaryl groups include 5-6 membered monocyclic heteroaryls and 8 - 10 membered bicyclic heteroaryls. Also included within the scope of the term "heterocycle, "heterocyclic" or "heterocyclyl" is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl or tetrahydro-quinolinyl, where the radical or point of attachment is on the non-aromatic heteroatom-containing ring. Unless otherwise indicated, the term "heterocycle, "heterocyclic" or "heterocyclyl" also included each possible positional isomer of a heterocyclic radical, such as in 1 -indolinyl, 2-indolinyl, 3-indolinyl. Examples of heterocycles include imidazolyl, imidazolinoyl, imidazolidinyl, quinolyl, isoquinolyl, indolyl, indazolyl, indazolinolyl, perhydropyridazyl, pyridazyl, pyridyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazinyl, quinoxolyl, piperidinyl, pyranyl, pyrazolinyl, piperazinyl, pyrimidinyl, pyridazinyl, morpholinyl, thiamorpholinyl, furyl, thienyl, triazolyl, thiazolyl, carbolinyl, tetrazolyl, thiazolidinyl, benzofuranoyl, thiamorpholinyl sulfone, oxazolyl, oxadiazolyl, benzoxazolyl, oxopiperidinyl, oxopyrrolidinyl, oxoazepinyl, azepinyl, isoxozolyl, isothiazolyl, furazanyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolyl, thiadiazoyl, dioxolyl, dioxinyl, oxathiolyl, benzodioxolyl, dithiolyl, thiophenyl, tetrahydrothiophenyl, sulfolanyl, dioxanyl, dioxolanyl, tetahydrofurodihydrofuranyl, tetrahydropyranodihydrofuranyl, dihydropyranyl, tetradyrofurofuranyl and tetrahydropyranofuranyl.
Optional substituents are hydroxy, halogen, amino and lower alkyl.
Protecting groups may be selected from groups known to those skilled in the art, including protecting groups disclosed in Greene, Theodora W.; Wuts, Peter G. M.. Protective Groups in Organic Synthesis. 2nd Ed. (1991),473 pp. or Kocienski, Philip J. Protecting Groups. 3rd Ed. 2005, (2005), 679 pp. The pyridone ring depicted in (1-1) and (N-Il), ie to which the -OP1 is directly attached, becomes in AA, BB and CC the ring shown next to the Q ring as follows:
Figure imgf000008_0001
Thus, the step P-2) can be carried out before or after creation of the Q ring, such steps for the creation of the Q ring being described herein and in WO 2006/1116764.
The present invention features a process as described above, wherein said step P-2) is carried out before creation of the Q ring and wherein said pyridone compound is of the formula AA or formula BB or formula CC.
The present invention features a process as described above, wherein said step P-2) is carried out after creation of the Q ring and wherein said pyridone compound is of the formula AA or formula BB or formula CC.
The present invention features a process as described above, wherein the pyridone compound is of the formula AA. The present invention features a process as described above, wherein the pyridone compound is of the formula BB.
The present invention features a process as described above, wherein the pyridone compound is of the formula CC.
Also part of the present invention are novel intermediates such as those of the following formula (DD) below:
DD
Figure imgf000008_0002
wherein P1 is as decribed above, particularly benzyl.
A process is provided for the preparation of a pyridone compound of the following formula (AA), (BB) or (CC):
Figure imgf000009_0001
Figure imgf000009_0002
Figure imgf000009_0003
comprising the steps of:
P-1) brominating a compound of the following formula (M) to produce a bromine compound of the following formula (H-Il):
Figure imgf000009_0004
l-l
wherein
R is -CHO, -CH(OH)2, -CH(OH)(OR4), -CH(OH)-CH2OH or — CH(OR5J(OR6); P1 is H or a hydroxyl protecting group; P3 is H or a carboxy protecting group; R4 is lower alkyl;
Rs and R6 are independently lower alkyl or R5 and R6 can be lower alkyl and joined to form a 5-, 6-, or 7-membered ring,
P-2) creating the 2,4-di-fluorophenyl-CH2-NH-C(O)- sidechain with the reactants 2,4-di-fluorophenyl-CH2-NH2 and carbon monoxide to form a compound of formula Ill-Ill
Figure imgf000010_0001
P-3) condensing and debenzylating a compound of formula Ill-Ill to form a compound of formula AA, BB, or CC.
The present invention also features processes as described above wherein P1 is benzyl; P3 is methyl; and R is -CHO, -CH(OH)(OR4), -CH(OR5)(OR5) wherein R4 and R5 are lower alkyl.
There is also described herein the process for the preparation of a compound of the following formula (I):
Figure imgf000010_0002
wherein
R is -CHO, -CH(OH)2 or -CH(OH)(OR4); P1 is H or a hydroxyl protecting group; P3 is H or a carboxy protecting group;
R3 is H, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted lower alkenyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterocyclic group, optionally substituted heterocycleoxy and optionally substituted amino; R4 is lower alkyl; Rx is H, halo or R2-X-NR1-C(O)-; R2 is optionally substituted aryl;
X is a single bond, a heteroatom group selected from O, S1 SO, SO2 , and NH or loweralkylene or lower alkenylene wherein each may be intervened by the heteroatom; and
R1 is H or lower alkyl, which comprises the steps of: i) reacting a compound of formula (II):
Figure imgf000011_0001
with an amine of formula (III) or (IV):
OR5
H9N (III)
OR6
wherein R5 and R6 are independently lower alkyl or R5 and R6 can be alkyl and joined to form a 5-, 6-, or 7-membered ring,
OH H2 N^k^0H (IV) to produce an intermediate of formula (V) or (Vl), respectively:
Figure imgf000011_0002
Figure imgf000012_0001
and ii) refunctionalizing (V) or (Vl) to produce (I). Specific compounds used in the processes include those of the following formulae (Ma)1 (Via), (VIb) and (Ia) utilized in Examples which follow:
Figure imgf000012_0002
Figure imgf000012_0003
Figure imgf000012_0004
Figure imgf000012_0005
The product (Ia) of a synthetic sequence can be condensed with an amine, eg of the formula H2NCI-I2CH2CH2OH, brominated if Rx is H1 carbonylated and amidated and finally, debenzylated to yield a compound of WO 2006/116764 designated (I-7) at page 240 wherein (R)m is 4-F and Ra is H. Alternatively, such a compound may be synthesized by starting with (I) where Rx is p-F-phenyl-CH2-NH-C(O)-, R3 is H, P1 is benzyl (Bn) and P3 is a carboxy protecting group.
In more detail, step i) can be carried out out in a protic or aprotic solvent such as EtOH, THF or DMF at a temperature of about 50-150° C for about 1-10 hours.
In more detail, step ii) can be carried out for the diol starting material (Vl) with an oxidizing agent such as NaIO4 , RuO4 or Pb(OAc)4 in a solvent such as H2O, MeOH or CH3CN at ambient temperature for one or more hours. For the acetal type starting material such as (V), reaction may be in an acid such as HCI, CF3COOH or HCOH optionally with heating.
Step ii) can also involve refunctionalization at the Rx postion, eg RX=H to R^Br optionally with further refunctionalization to RX=R2-X-NR1-C(O)-. Step ii) can also involve refunctionalization of P3, eg P3=H to P3=Me.
In more detail, step P-1) can be carried out by treating a compound of formula l-l with a bromine source including but not limited to Λ/-bromosuccinimide or bromine in a solvent such as Λ/,Λ/-dimethyl formamide, THF or acetic acid and the like. This transformation can be run particularly at a temperature of -10 0C to 500C to produce a compound of formula H-Il.
In more detail, step P-2) can be carried out by treating a compound of formula H-Il with 2,4-difluorophenyl-CH2-NH2l carbon monoxide, a suitable base and palladium (0) source and optionally an appropriate ligand in an inert solvent optionally with heating. The carbon monoxide can be at atmospheric pressure (14.7 psi) or at elevated pressure particularly in the range of up to 60 psi but in some cases higher pressures may be required. Bases include but are not limited to tertiary amine bases such as diisopropylethylamine and triethylamine and the like. Inorganic bases such as potassium acetate and potassium phosphate are also bases of significance. Suitable sources of Pd (0) include but are not limited to tetrakis triphenylphosphine palladium (0). In some cases a Pd (II) precursor can be used to generate Pd (0) in situ. Suitable Pd (II) precursors include but are not limited to Pd(OAc)2, Pd(OCOCF3)2 and ligands include Xantphos, diphenylphosphinoferrocene (dppf), triphenylphosphine and the like. Solvents include Λ/./v-dimethyl formamide, THF1 toluene, DMSO and the like. Heating the mixture is optionally used in the range from ambient to 1500C
The present invention also features crystalline forms of a compound of formula AA (Compound 13, Example 1) salt and a hydrate thereof. The present invention features:
(1) A salt or a hydrate thereof of a compound of formula AA:
Figure imgf000014_0001
(2) A crystal form of a sodium salt or a hydrate thereof of a compound of formula AA:
Figure imgf000014_0002
(3) A crystal form of (2) having one or more physical properties selected from the group consisting of (i) and (ii):
(i) having characteristic diffraction peaks at 6.4° ± 0.2°, 9.2° ± 0.2°, 13.8° ± 0.2°, 19.2° ± 0.2° and 21.8° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern; and (ii) having characteristic infrared absorption spectra at 1641cm"1 ± 2cm"1, 1536cm"1 ± 2cm" \ 1503cm"1 ± 2cm"1 and 1424cm"1 ± 2cm"1.
(4) A crystal form of (2) having characteristic diffraction peaks at 6.4° ± 0.2°, 9.2° ± 0.2°,
13.8° ± 0.2°, 19.2° ± 0.2° and 21.8° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.
(5) A crystal form of (2) having characteristic diffraction peaks at 6.4° ± 0.2°, 9.2° ± 0.2°, 13.8° ± 0.2°, 14.6° ± 0.2°, 15.2° ± 0.2°, 17.6" ± 0.2°, 19.2° ± 0.2°, 21.8° ± 0.2°, 24.1° ± 0.2° and 28.7° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.
(6) A crystal form of (2) having characteristic infrared absorption spectra at 1641cm"1 ± 2cm"1 , 1536cm"1 ± 2cm"1 , 1503cm"1 ± 2cm'1 and 1424cm"1 ± 2cm"1. (7) A crystal form of (2) having characteristic infrared absorption spectra at 1641cm'1 ± 2cm"1, 1536cm 1 ± 2cm'1, 1503cm 1 ± 2cm"1, 1424cm 1 ± 2crτϊ1, 1282cm"1 ± 2cm 1, 1258cm 1 ± 2cm"1, 1093cm"1 ± 2cm'1 and 1069cm"1 ± 2cm"1.
(8) A crystal form of (2) having one or more spectra selected from the group consisting of (a) to (C):
(a) X-ray powder diffraction pattern substantially as shown in Figure 1 ;
(b) Infrared absorption spectra substantially as shown in Figure 2; and
(c) Solid state 13C-NMR spectra substantially as shown in Figure 3.
(9) A crystal form of (2) having one or more physical properties selected from the group consisting of (iii) and (iv):
(iii) having characteristic diffraction peaks at 8.0° ± 0.2°, 9.3° ± 0.2°, 11.3° ± 0.2°, 16.0° ± 0.2°, and 22.8° ± 0.2°degrees two-theta in an X-ray powder diffraction pattern; and (iv) having characteristic infrared absorption spectra at 1637cm"1 ± 2cm"1, 1536cm"1 ± 2cm" \ 1501cm"1 ± 2cm"1 and 1422cm"1 ± 2cm"1.
(10) A crystal form of (2) having characteristic diffraction peaks at 8.0° ± 0.2°, 9.3° ± 0.2°, 11.3° ± 0.2°, 16.0° ± 0.2°and 22.8° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.
(11) A crystal form of (2) having characteristic diffraction peaks at 8.0° ± 0.2°, 9.3° ± 0.2°, 11.3° ± 0.2°, 15.4° ± 0.2°, 16.0° ± 0.2°, 18.7° ± 0.2°, 19.1° ± 0.2°, 19.8° ± 0.2°, 22.8° ± 0.2° and 26.8° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.
(12) A crystal form of (2) having characteristic infrared absorption spectra at 1637cm"1 ±
2cm"1, 1536cm"1 ± 2cm"1, 1501cm"1 ± 2cm'1 and 1422cm"1 ± 2cm'1.
(13) A crystal form of (2) having characteristic infrared absorption spectra at 1637cm"1 ± 2cm'1, 1536cm"1 ± 2cm'1, 1501cm"1 ± 2cm"1, 1422cm"1 ± 2cm"1, 1277cm"1 ± 2cm"1, 1258cm'1
± 2cm"1, 1093cm"1 ± 2cm"1 and 1069cm"1 ± 2cm"1.
(14) A crystal form of (2) having one or more spectra selected from the group consisting of (d) and (e): (d) X-ray powder diffraction pattern substantially as shown in Figure 4; and (e) Infrared absorption spectra substantially as shown in Figure 5.
(15) A pharmaceutical composition containing the crystal form as defined in any one of
(2) to (14). (16) A process for preparation of the crystal forms as defined in any one of (2) to (14).
The present invention features crystalline forms of a salt of compound of formula AA, in particular a sodium salt.
The present invention features crystalline forms of a hydrate of a salt of a compound of formula AA, in particular a sodium salt.
This invention also includes a crystal form of a compound of formula AA (Compound 12, Example 1). Details are shown as (17) to (22):
(17) A crystal form of a compound of formula AA:
Figure imgf000016_0001
having one or more physical properties selected from the group consisting of (v) and (vi): (v) having characteristic diffraction peaks at 5.4° ± 0.2°, 10.7° ± 0.2°, 12.3° ± 0.2°, 15.2° ± 0.2°, and 16.4° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern; and (vi) having characteristic infrared absorption spectra at 1658cm"1 ± 2cm"1, 1628cm"1 ± 2cm" \ 1540cm"1 ± 2cm"1 and 1498cm"1 ± 2cm"1.
(18) A crystal form of a compound of formula AA:
Figure imgf000016_0002
having characteristic diffraction peaks at 5.4° ± 0.2°, 10.7° ± 0.2°, 12.3° ± 0.2°, 15.2° ± 0.2°and 16.4° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.
(19) A crystal form of a compound of formula AA:
Figure imgf000017_0001
having characteristic diffraction peaks at 5.4° ± 0.2°, 10.7° ± 0.2°, 12.3° ± 0.2°, 14.3° ± 0.2°, 15.2° ± 0.2°, 16.4° ± 0.2°, 21.7° ± 0.2°, 24.9° ± 0.2°, 25.4° ± 0.2° and 27.9° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.
(20) A crystal of a compound of formula AA:
Figure imgf000017_0002
having characteristic infrared absorption spectra at 1658cm'1 ± 2cm"1, 1628cm"1 ± 2cm"1, 1540cm"1 ± 2cm"1 and 1498cm"1 ± 2cm"1.
(21) A crystal of a compound of formula AA:
Figure imgf000017_0003
having characteristic infrared absorption spectra at 1658cm"1 ± 2cm"1, 1628cm"1 ± 2cm"1, 1540cm"1 ± 2cm"1, 1498cm"1 ± 2cm"1, 1355cm"1 ± 2cm"1, 1264cm"1 ± 2cm"1, 1238cm"1 ± 2cm" 1 , 1080cm"1 ± 2cm"1 and 1056cm"1 ± 2cm"1.
(22) A crystal of a compound of formula AA:
Figure imgf000017_0004
having one or more spectra selected from the group consisting of (f) and (g): (f) X-ray powder diffraction pattern substantially as shown in Figure 6; and (g) Infrared absorption spectra substantially as shown in Figure 7.
The crystals of compound 13 and 13b (monohydrate form of compound 13) demonstrate high solubility in water or saline, high bioavailability (BA), high maximum drug concentration (Cmax), short maximum drug concentration time (Tmax), high stability against heat or light, and/or good handling facility. Therefore, the crystals of compound 13 and 13b are suitable as pharmaceutical ingredients.
In the following examples and throughout this specification, the following abbreviations may be used: Me (methyl), Bn (benzyl), Aq (aqueous), Et (ethyl), C (centrigrade).
[EXAMPLES
In the following Examples, those depicting the bromination and amidation reactions of the present invention include Examples C, Example 2 and Example CC.
The following examples are intended for illustration only and are not intended to limit the scope of the invention in any way.
Examples 1 and 3
The starting material of Example 1e and 3e is the compound of formula (Ha) which is also shown as compound 5 below and compound #101 at page 113 of WO 2006/116764. The product depicted below as compound 8 is of the formula (I). The final product shown below as compound 13 is a compound of formula (I-7) at page 240 of WO 2006/116764 wherein (R)n, is 2,4-di-F and Ra is H, provided, however, that there is an alpha methyl at the position designated R16 in formula (XXVI) at page 65.
N X r>Bn I) RuCI3ZNaIO4
Figure imgf000019_0002
Figure imgf000019_0001
2 3
Figure imgf000019_0003
13
Thus, in the above sequence for Example 1, compound 5 is identical to compound 101 at page 113 of WO 2006/116764 and to formula (Ha) of the process of the present invention; compound 6 above is identical to formula (Via) of the process of the present invention; compound 7 above is identical to formula (VIb) of the process of the present invention; and compound 8 is identical to formula (Ia) of the process of the present invention. Step i) of the invention process is S to 6 above while step ii) is 6 to 8.
Example 1a To a slurry of 2000 g of compound 1(1.0 eq.) in 14.0 L of MeCN were added 2848 g of benzyl bromide(1.05 eq.) and 2630 g of K2CO3(1.2 eq.). The mixture was stirred at 80 0C for 5 h and cooled to 13°C. Precipitate was filtered and washed with 5.0 L of MeCN. The filtrate was concentrated and 3.0 L of THF was added to the residue. The THF solution was concentrated to give 3585 g of crude compound 2 as oil. Without further purification, compound 2 was used in the next step.
1H NMR(300 MHz, CDCI3) δ 7.60 (d, J = 5.7 Hz, 1H), 7.4-7.3 (m, 5H), 6.37 (d, J = 5.7 Hz, 1H), 5.17 (s, 2H), 2.09 (s, 3H). Example 1 b
To 904 g of the crude compound 2 was added 5.88 L of THF and the solution was cooled to -60 0C. 5.00 L of 1.0 M of Lithium bis(trimethylsilylamide) in THF(1.25 eq.) was added dropwise for 2 h to the solution of compound 2 at -60 °C. Then, a solution of 509 g of benzaldehyde(1.2 eq.) in 800 ml_ of THF was added at -60 °C and the reaction mixture was aged at -60 0C for 1 h. The THF solution was poured into a mixture of 1.21 L of conc.HCI, 8.14 L of ice water and 4.52 L of EtOAc at less than 2 0C. The organic layer was washed with 2.71 L of brine (twice) and the aqueous layer was extracted with 3.98 L of EtOAc. The combined organic layers were concentrated. To the mixture, 1.63 L of toluene was added and concentrated (twice) to provide toluene slurry of compound 3. Filtration, washing with 0.90 L of cold toluene and drying afforded 955 g of compound 3 (74% yield from compound 1) as a crystal.
1H NMR(300 MHz, CDCI3) δ 7.62 (d, J = 5.7 Hz, 1H), 7.5-7.2 (m, 10H), 6.38 (d, J = 5.7 Hz, 1H), 5.16 (d, J = 11.4 Hz, 1H), 5.09 (d, J = 11.4 Hz, 1H), 4.95 (dd, J = 4.8, 9.0 Hz, 1H), 3.01 (dd, J = 9.0, 14.1 Hz, 1H), 2.84 (dd, J = 4.8, 14.1 Hz, 1H).
Example 1c
To a solution of 882 g of compound 3 (1.0 eq.) in 8.82 L of THF were added 416 g of
Et3N(1.5 eq.) and 408 g of methanesulfonyl chloride(1.3 eq.) at less than 30 0C. After confirmation of disappearance of compound 3, 440 ml_ of NMP and 1167 g of DBU(2.8 eq.) were added to the reaction mixture at less than 30 0C and the reaction mixture was aged for 30 min. The mixture was neutralized with 1.76 L of 16% sulfuric acid and the organic layer was washed with 1.76 L of 2% Na2S03aq. After concentration of the organic layer, 4.41 L of toluene was added and the mixture was concentrated (tree times). After addition of 4.67 L of hexane, the mixture was cooled with ice bath. Filtration, washing with 1.77 L of hexane and drying provided 780 g of compound 4 (94% yield) as a crystal. 1H NMR(300 MHz, CDCI3) δ 7.69 (d, J = 5.7 Hz, 1H), 7.50-7.25 (m, 10H), 7.22 (d, J = 16.2 Hz, 1H), 7.03 (d, J = 16.2 Hz, 1H), 6.41 (d, J = 5.7 Hz, 1H), 5.27 (s, 2H).
Example 1d
To a mixture of 822 g of compound 4 (1.0 eq.) and 11.2 g of RuCI3 nH2O(0.02 eq.) in 2.47 L of MeCN, 2.47 L of EtOAc and 2.47 L of H2O was added 2310 g of NalO4(4.0 eq.) at less than 25 °C. After aging for 1 h, 733 g of NaCIO2(3.0 eq.) was added to the mixture at less than 25 °C. After aging for 1 h, precipitate was filtered and washed with 8.22 L of EtOAc. To the filtrate, 1.64 L of 50% Na2S2O3aq, 822 mL of H2O and 630 mL of coc.HCI were added. The aqueous layer was extracted with 4.11 L of EtOAc and the organic layers were combined and concentrated. To the residue, 4 L of toluene was added and the mixture was concentrated and cooled with ice bath. Filtration, washing with 1 L of toluene and drying provided 372 g of compound 5 (56% yield) as a crystal. 1H NMR(300 MHz, CDCI3) δ 7.78 (d, J = 5.7 Hz1 1H), 7.54-7.46 (m, 2H), 7.40-7.26 (m, 3H), 6.48 (d, J = 5.7 Hz, 1 H), 5.6 (brs, 1 H), 5.31 (s, 2H).
Example 1e
A mixture of 509 g of compound 5 (1.0 eq.) and 407 g of 3-amino-propane-1,2-diol(2.5 eq.) in 1.53 L of EtOH was stirred at 65 0C for 1 h and at 80 0C for 6 h. After addition of 18.8 g of 3-Amino-propane-1,2-diol(0.1 eq.) in 200 mL of EtOH, the mixture was stirred at 80 °C for 1 h. After addition of 18.8 g of 3-arnino-propane-1 ,2-diol (0.1 eq.) in 200 mL of EtOH, the mixture was stirred at 80 °C for 30 min. After cooling and addition of 509 mL of H2O1 the mixture was concentrated. To the residue, 2.54 L of H2O and 2.54 L of AcOEt were added. After separation, the aqueous layer was washed with 1.02 L of EtOAc. To the aqueous layer, 2.03 L of 12% sulfuric acid was added at less than 12 "C to give crystal of compound 6. Filtration, washing with 1.53 L of cold H2O and drying provided 576 g of compound 6 (83% yield) as a crystal.
1H NMR(300 MHz, DMSO-cfe) δ 7.67 (d, J = 7.5 Hz, 1H), 7.5-7.2 (m, 5H), 6.40 (d, J = 7.5 Hz, 1H), 5.07 (s, 2H), 4.2^t.O (m, 1H), 3.9-3.6 (m, 2H), 3.38 (dd, J = 4.2, 10.8 Hz, 1H), 3.27 (dd, J = 6.0, 10.8 Hz1 1H).
Example 1f
To a slurry of 576 g of compound 6(1.0 eq.: 5.8% of H2O was contained) in 2.88 L of NMP were added 431 g of NaHCO3(3.0 eq.) and 160 mL of methyl iodide(1.5 eq.) and the mixture was stirred at room temperature for 4 h. After cooling to 5 "C, 1.71 L of 2N HCI and 1.15 L of 20% NaClaq were added to the mixture at less than 10 0C to give crystal of compound 7. Filtration, washing with 1.73 L of H2O and drying provided 507 g of compound 7 (89% yield) as a crystal. 1H NMR(300 MHz, DMSO-cfe) δ 7.59 (d, J = 7.5 Hz, 1H), 7.40-7.28 (m, 5H), 6.28 (d, J = 7.5 Hz, 1H), 5.21 (d, J = 5.4 Hz, 1H), 5.12 (d, J = 10.8 Hz, 1H), 5.07 (d, J = 10.8 Hz, 1H)1 4.83 (t, J = 5.7 Hz, 1 H), 3.97 (dd, J = 2.4, 14.1 Hz1 1 H), 3.79 (s, 3H), 3.70 (dd, J = 9.0, 14.4 Hz, 1H), 3.65-3.50 (m, 1H)1 3.40-3.28 (m, 1H), 3.26-3.14 (m, 1H).
Example 1g To a mixture of 507 g of compound 7(1.0 eq.) in 5.07 L of MeCN, 5.07 L of H2O and 9.13 g of AcOH(0.1 eq.) was added 390 g of NaIO4(1.2 eq.) and the mixture was stirred at room temperature for 2 h. After addition of 1.52 L of 10% Na2S2O3aq., the mixture was concentrated and cooled to 10 0C. Filtration, washing with H2O and drying provided 386 g of compound 8 (80% yield) as a crystal.
1H NMR(300 MHz, DMSO-d6) δ 7.62 (d, J = 7.5 Hz, 1H)1 7.42-7.30 (m, 5H), 6.33 (d, J = 6.0 Hz, 2H), 6.29 (d, J = 7.5 Hz, 1 H)1 5.08 (s, 2H), 4.95-4.85 (m, 1 H)1 3.80 (S1 3H), 3.74 (d, J = 5.1 Hz1 2H).
Example 1 h
After dissolution of a mixture of 378 g of compound 8 (1.0 eq.) in 3.78 L of MeOH by heating, the solution was concentrated. To the residue, 1.51 L of toluene was added and the mixture was concentrated. To the residue, 1.89 L of toluene, 378 mL of AcOH and 137 g of (ft)-3-Amino-butan-1-ol(1.3 eq.) were added and the mixture was heated to 90 °C, stirred at 90 0C for 2.5 h and concentrated. To the residue, 1.89 L of toluene was added and the mixture was concentrated. The residue was extracted with 3.78 L and 1.89 L of CHCI3 and washed with 2 x 1.89 L of H2O. The organic layers were combined and concentrated. To the residue, 1.89 L of EtOAc was added and the mixture was concentrated. After addition of 1.89 L of EtOAc, filtration, washing with 1.13 L of EtOAc and drying provided 335 g of compound 9 (83% yield) as a crystal. 1H NMR(300 MHz, CDCI3) δ 7.70-7.58 (m, 2H), 7.40-7.24 (m, 3H), 7.14 (d, J = 7.5 Hz, 2H), 6.47 (d, J = 7.5 Hz, 1H), 5.35 (d, J = 10.2 Hz, 1H), 5.28 (d, J = 10.2 Hz, 1H), 5.12 (dd, J = 3.9, 6.3 Hz, 1 H), 5.05-4.90 (m, 1 H), 4.07 (dd, J = 3.9, 13.5 Hz, 1 H), 4.00-3.86 (m, 3H), 2.23-2.06 (m, 1H), 1.48 (ddd, J = 2.4, 4.5, 13.8 Hz, 1H), 1.30 (d, J = 6.9 Hz, 3H).
Example 1i To a slurry of 332 g of compound 9 (1.0 eq.) in 1.66 L of NMP was added 191 g of
NBS(1.1 eq.) and the mixture was stirred at room temperature for 2 h. After addition of 1.26 L of H2O, the mixture was stirred for 30 min. After addition of 5.38 L of H2O and aging of the mixture at 10 0C for 30 min and at 5 0C for 1 h, filtration, washing with 1.33 L of cold H2O and drying provided 362 g of compound 10 (89% yield) as a crystal. 1H NMR(300 MHz, CDCI3) δ 7.69-7.63 (m, 2H), 7.59 (s, 1H), 7.38-7.24 (m. 3H), 5.33 (d, J = 10.2 Hz, 1H), 5.25 (d, J = 9.9 Hz, 1H), 5.12 (dd, J = 3.9, 5.7 Hz, 1H), 5.05-4.90 (m, 1H), 4.11 (dd, J = 3.9, 13.2 Hz, 1H), 4.02-3.88 (m, 3H), 2.21-2.06 (m, 1H)1 1.49 (ddd, J = 2.4, 4.5, 14.1 Hz, 1H), 1.31 (d, J = 6.9 Hz1 3H).
Example 1j Under carbon mono-oxide atmosphere, a mixture of 33.5 g of compound 10(1.0 eq.), 34.8 ml_ of /-Pr2NEt(2.5 eq.), 14.3 ml_ of 2,4-difluorobenzylamine(1.5 eq.) and 4.62 g of Pd(PPh3)4(0.05 eq.) in 335 mL of DMSO was stirred at 90 0C for 5.5 h. After cooling, precipitate was filtered and washed with 50 mL of 2-propanol. After addition of 502 mL of H2O and 670 mL of AcOEt to the filtrate, the organic layer was washed with 335 mL of 0.5N HCIaq. and 335 mL of H2O and the aqueous layer was extracted with 335 mL of AcOEt. The organic layers were combined and concentrated. To the residue, 150 mL of 2-propanol was added and the mixture was concentrated. After addition of 150 mL of 2- propanol, concentration, cooling to 20 °C and filtration, crude crystal of compound 11 was obtained. After dissolution of the crude crystal in 380 mL of acetone by heating, precipitate was filtered and the filtrate was concentrated. After addition of 200 mL of EtOH, concentration, addition of 150 mL of EtOH, concentration, cooling and filtration, crude crystal of compound 11 was obtained. After dissolution of the crude crystal in 450 mL of acetone by heating, the solution was concentrated. To the residue, 150 mL of 2- propanol was added and the mixture was concentrated (twice). After cooling of the residue, filtration, washing with 2-propanol and drying provided 34.3 g of compound 11 (84% yield) as a crystal.
1H NMR(300 MHz, CDCI3) δ 10.40 (t, J = 6.0 Hz, 1H), 8.35 (s, 1H), 7.66-7.58 (m, 2H), 7.42-7.24 (m, 5H), 6.78-6.74 (m, 2H), 5.30 (d, J = 9.9 Hz, 1H), 5.26 (d, J = 10.2 Hz, 1H), 5.15 (dd, J = 3.9, 5.7 Hz, 1H), 5.05-4.90 (m, 1H)1 4.64 (d, J = 5.4 Hz, 2H), 4.22 (dd, J =
3.9, 13.5, 1 H), 4.09 (dd, J = 6.0, 13.2 Hz, 1 H), 4.02-3.88 (m, 2H), 2.24-1.86 (m, 1 H), 1.50 (ddd, J = 2.4, 4.5, 14.1 Hz, 1H), 1.33 (d, J = 7.2 Hz, 3H).
Example 1k Under hydrogen atmosphere, a mixture of 28.0 g of compound 11 (1.0 eq.) and 5.6 g of 10% Pd-C in 252 mL of THF and 28 mL of MeOH was stirred for 1 h. After precipitate (Pd-C) was filtered and washed with 45 mL of THF, 5.6 g of 10% Pd-C was added and the mixture was stirred for 1.5 h under hydrogen atmosphere. After Pd-C was filtered and washed with 150 mL of CHCl3/MeOH(9/1 ), the filtrate was concentrated. After dissolution of the residue in 1.38 L of EtOH by heating, the solution was gradually cooled to room temperature. After filtration, the filtrate was concentrated and cooled. Filtration, washing with EtOH and drying provided 21.2 g of compound 12 (92% yield) as a crystal. 1H NMR(300 MHz, DMSO-d6) δ 12.51 (s, 1H), 10.36 (X, J = 5.7 Hz, 1 H), 8.50 (s, 1H), 7.39 (td, J = 8.7, 6.3 Hz, 1H), 7.24 (ddd, J = 2.6, 9.5, 10.8 Hz, 1H), 7.12-7.00 (m, 1H), 5.44 (dd, J = 3.9, 5.7 Hz, 1H), 4.90-4.70 (m, 1H), 4.65-4.50 (m, 1H), 4.54 (d, J = 5.1 Hz, 2H), 4.35 (eld, J = 6.0, 13.8 Hz, 1H), 4.10-3.98 (m, 1H), 3.96-3.86 (m, 1H)1 2.10-1.94 (m, 1H), 1.60-1.48 (m, 1 H), 1.33 (d, J = 6.9 Hz1 3H).
Example 11 After dissolution of 18.0 g of compound 12 (1.0 eq.) in 54 mL of EtOH by heating, followed by filtration, 21.5 mL of 2N NaOHaq.(1.0 eq.) was added to the solution at 80 0C. The solution was gradually cooled to room temperature. Filtration, washing with 80 mL of EtOH and drying provided 18.8 g of compound 13 (99% yield) as a crystal. 1H NMR(300 MHz, DMSO-cfe) δ 10.70 (t, J = 6.0 Hz, 1H), 7.89 (s, 1H), 7.40-7.30 (m, 1H), 7.25-7.16 (m, 1H), 7.06-6.98 (m, 1H), 5.22-5.12 (m, 1H), 4.87-4.74 (m, 1H), 4.51 (d, J = 5.4 Hz, 2H), 4.35-4.25 (m, 1H), 4.16 (dd, J = 1.8, 14.1 Hz, 1H), 4.05-3.90 (m, 1H), 3.86- 3.74 (m, 1 H), 2.00-1.72 (m, 1 H), 1.44-1.32 (m, 1 H), 1.24 (d, J = 6.9 Hz, 3H).
Example 1m Example 1m shows a process for preparation of the crystalline compound 13b which is monohydrate form of compound 13.
After dissolution of 30.0 g of compound 13 (1.0 eq.) in 600 mL of THF-water solution (8:2) by 30 0C, 36.OmL of 2N NaOHaq (1.0 eq.) was added to the solution. The mixture was stirred at room temperature for 2 hours. The precipitation was filtered, washing with 150 mL of THF-water solution (8:2), 150 mL of THF. Drying at 85 0C and humidity conditioning provided 30.4 g of compound 13b (monohydrate form of compound 13, 93% yield) as a crystal.
Example 3
Example 3a
To a slurry of 2000 g of compound 1(1.0 eq.) in 14.0 L of MeCN were added 2848 g of benzyl bromide(1.05 eq.) and 2630 g of K2CO3(1.2 eq.). The mixture was stirred at 80 0C for 5 h and cooled to 13°C. Precipitate was filtered and washed with 5.0 L of MeCN. The filtrate was concentrated and 3.0 L of THF was added to the residue. The THF solution was concentrated to give 3585 g of crude compound 2 as oil. Without further purification, compound 2 was used in the next step.
1H NMR(300 MHz1 CDCI3) δ 7.60 (d, J = 5.7 Hz, 1H), 7.4-7.3 (m, 5H), 6.37 (d, J = 5.7 Hz, 1H), 5.17 (S, 2H), 2.09 (s, 3H).
Example 3b To 904 g of the crude compound 2 was added 5.88 L of THF and the solution was cooled to -60 0C. 5.00 L of 1.0 M of Lithium bis(trimethylsilylamide) in THF(1.25 eq.) was added dropwise for 2 h to the solution of compound 2 at -60 0C. Then, a solution of 509 g of benzaldehyde(1.2 eq.) in 800 mL of THF was added at -60 "C and the reaction mixture was aged at -60 0C for 1 h. The THF solution was poured into a mixture of 1.21 L of conc.HCI, 8.14 L of ice water and 4.52 L of EtOAc at less than 2 0C. The organic layer was washed with 2.71 L of brine (twice) and the aqueous layer was extracted with 3.98 L of EtOAc. The combined organic layers were concentrated. To the mixture, 1.63 L of toluene was added and concentrated (twice) to provide toluene slurry of compound 3. Filtration, washing with 0.90 L of cold toluene and drying afforded 955 g of compound 3 (74% yield from compound 1) as a crystal.
1H NMR(300 MHz, CDCI3) δ 7.62 (d, J = 5.7 Hz, 1H), 7.5-7.2 (m, 10H), 6.38 (d, J = 5.7 Hz1 1H), 5.16 (d, J = 11.4 Hz, 1H)1 5.09 (d, J = 11.4 Hz1 1H)1 4.95 (dd. J = 4.8, 9.0 Hz, 1H), 3.01 (dd, J = 9.0, 14.1 Hz1 1H), 2.84 (dd, J = 4.8, 14.1 Hz, 1H).
Example 3c
To a solution of 882 g of compound 3 (1.0 eq.) in 8.82 L of THF were added 416 g of
Et3N(1.5 eq.) and 408 g of methanesulfonyl chloride(1.3 eq.) at less than 30 0C. After confirmation of disappearance of compound 3, 440 mL of NMP and 1167 g of DBU(2.8 eq.) were added to the reaction mixture at less than 30 °C and the reaction mixture was aged for 30 min. The mixture was neutralized with 1.76 L of 16% sulfuric acid and the organic layer was washed with 1.76 L of 2% Na2S03aq. After concentration of the organic layer, 4.41 L of toluene was added and the mixture was concentrated (tree times). After addition of 4.67 L of hexane, the mixture was cooled with ice bath. Filtration, washing with 1.77 L of hexane and drying provided 780 g of compound 4 (94% yield) as a crystal.
1H NMR(300 MHz1 CDCI3) δ 7.69 (d, J = 5.7 Hz1 1H), 7.50-7.25 (m, 10H)1 7.22 (d, J = 16.2 Hz, 1H), 7.03 (d, J= 16.2 Hz, 1H), 6.41 (d, J = 5.7 Hz, 1H), 5.27 (s, 2H).
Example 3d To a mixture of 10.0 g of compound 4 and 13.6 mg of RuCI3 nH2O in 95 mL of MeCN and
10 mL of water, mixture of 155mL of water, 7.2 g of hydrosulfuric acid, and 15.5 g of Nalθ4was added for 2.5 h at 20 °C. After aging for 1 h, organic and aqueous layers were separated and aqueous layer was exracted by 3OmL of ethyl acetate. Aqueous layer was exracted again by 3OmL of ethyl acetate and organic layers were combined. 6 mL of 5% NaHSO3 solution was added to the combined organic layer and the layers were separated. The organic layer was adjusted to pH 6.0 by adding 4.Og of 2M NaOH solution and the aqueous layer was separated. After 60 mL of 5% NaHCO3 solution and 257mg of TEMPO was added, 25.9 g of NaCIO solution was added to the reaction mixture at 25 0C for 1 h and stirred for 30min to check the reaction was finished. After the layers were separated, 42.5mL of 5% Na2SO3 solution and 3OmL of AcOEt were added and separated. The aqueous layer was exracted by 3OmL of AcOEt and separated. 12% H2SO4 was added to the reaction mixture at 20 °C for 1h and the mixture was cooled to 5 °C. After the mixture was stirred for 30 min, the mixture was filtered, washed with 30 mL of water twice and dryed to provide 5.7 g of compound 5 (70% yield) as a crystal.
1H NMR(300 MHz, CDCI3) δ 7.78 (d, J = 5.7 Hz, 1H), 7.54-7.46 (m, 2H), 7.40-7.26 (m, 3H)1 6.48 (d, J = 5.7 Hz, 1H), 5.6 (brs, 1H), 5.31 (s, 2H).
Example 3e
A mixture of 509 g of compound 5 (1.0 eq.) and 407 g of 3-amino-propane-1 ,2-diol(2.5 eq.) in 1.53 L of EtOH was stirred at 65 °C for 1 h and at 80 0C for 6 h. After addition of 18.8 g of 3-Amino-propane-1,2-diol(0.1 eq.) in 200 mL of EtOH, the mixture was stirred at 80 0C for 1 h. After addition of 18.8 g of 3-amino-propane-1 ,2-diol (0.1 eq.) in 200 mL of EtOH, the mixture was stirred at 80 0C for 30 min. After cooling and addition of 509 mL of H2O, the mixture was concentrated. To the residue, 2.54 L of H2O and 2.54 L of AcOEt were added. After separation, the aqueous layer was washed with 1.02 L of EtOAc. To the aqueous layer, 2.03 L of 12% sulfuric acid was added at less than 12 0C to give crystal of compound 6. Filtration, washing with 1.53 L of cold H2O and drying provided 576 g of compound 6 (83% yield) as a crystal.
1H NMR(300 MHz1 DMSO-cfe) δ 7.67 (d, J = 7.5 Hz, 1 H)1 7.5-7.2 (m, 5H)1 6.40 (d, J = 7.5 Hz1 1H), 5.07 (s, 2H), 4.2-4.0 (m, 1H)1 3.9-3.6 (m, 2H), 3.38 (dd, J = 4.2, 10.8 Hz1 1H), 3.27 (dd, J = 6.0, 10.8 Hz, 1H).
Example 3f
To a slurry of 576 g of compound 6 (1.0 eq.: 5.8% of H2O was contained) in 2.88 L of
NMP were added 431 g of NaHCO3 (3.0 eq.) and 160 mL of methyl iodide(1.5 eq.) and the mixture was stirred at room temperature for 4 h. After cooling to 5 0C, 1.71 L of 2N HCI and 1.15 L of 20% NaClaq were added to the mixture at less than 10 0C to give crystal of compound 7. Filtration, washing with 1.73 L of H2O and drying provided 507 g of compound 7 (89% yield) as a crystal.
1H NMR(300 MHz, DMSO-Cf6) δ 7.59 (d, J = 7.5 Hz1 1H), 7.40-7.28 (m, 5H), 6.28 (d, J =
7.5 Hz, 1H), 5.21 (d, J = 5.4 Hz1 1H)1 5.12 (d, J = 10.8 Hz, 1H), 5.07 (d, J = 10.8 Hz, 1H), 4.83 (t, J = 5.7 Hz1 1 H)1 3.97 (dd, J = 2.4, 14.1 Hz, 1 H)1 3.79 (s, 3H), 3.70 (dd, J = 9.0.
14.4 Hz1 1H)1 3.65-3.50 (m, 1H)1 3.40-3.28 (m, 1H), 3.26-3.14 (m, 1H). Example 3g
To a mixture of 15.0 g of compound 7(1.0 eq.) in 70.9 g of MeCN, a mixture of 60 mL of
H2O, 2.6 g of H2SO4 and 11.5 g of NaIO4 was added in the range between 17 0C to 14°C. After the reaction mixture was stirred for 1 hour, precipitate was filtered. The filterate was added to the solution of 11.8 g of ascorbic acid sodium salt, 64 g of water and 60mg of H2SO4. After the mixture was concentrated, cooling to 5 0C, filtration, washing with H2O and drying provided 12.9 g of compound 8 (90% yield) as a crystal.
1H NMR(300 MHz, DMSO-cfe) δ 7.62 (d, J = 7.5 Hz, 1H), 7.42-7.30 (m, 5H), 6.33 (d, J = 6.0 Hz1 2H), 6.29 (d, J = 7.5 Hz, 1H), 5.08 (s, 2H), 4.95-4.85 (m, 1H), 3.80 (s, 3H), 3.74 (d, J = 5.1 Hz, 2H).
Example 3h
A mixture of 10.0 g of compound 8 and 33.3 g of diglyme were added the solution of 3.3 g of (F?)-3-Amino-butan-1-ol in 4.7 g of diglyme and 1.0 g of acetic acid at 600C. After the reaction mixture was stirred at 95 °C for 9 hours, the reaction mixture was cooled to -5 0C and filtered. The wet crystal was washed and dryed to give 8.3 g of compound 9 (78%). XRD data:
1H NMR(300 MHz, CDCI3) δ 7.70-7.58 (m, 2H), 7.40-7.24 (m, 3H), 7.14 (d, J = 7.5 Hz, 2H), 6.47 (d, J = 7.5 Hz, 1H), 5.35 (d, J = 10.2 Hz, 1H), 5.28 (d, J = 10.2 Hz, 1H), 5.12 (dd, J = 3.9, 6.3 Hz, 1 H), 5.05-^.90 (m, 1 H), 4.07 (dd, J = 3.9, 13.5 Hz, 1 H), 4.00-3.86 (m, 3H), 2.23-2.06 (m, 1 H), 1.48 (ddd, J = 2.4, 4.5, 13.8 Hz, 1 H), 1.30 (d, J = 6.9 Hz, 3H).
Example 3i
To slurry of 5.7 g of NBS in 26.5 g of dichloromethane was added 10 g of compound 9 in 92.8 g of dichloromethane at room temperature. After thr reaction mixture was stirred for 6.5h, the reaction mixture was added to the solution of 2.Og Na2SO3 and 40.3 g of water. The organic layer was washed with diluted NaOH solution and water, dichloromethane was concentrated and was displaced by methanol. The mixture was cooled to -5 °C and filtered and the wet crystal was washed and dryed to give 10.3 g of compound 10 (84%). 1H NMR(300 MHz, CDCI3) δ 7.69-7.63 (m, 2H), 7.59 (s, 1 H), 7.38-7.24 (m, 3H), 5.33 (d, J = 10.2 Hz, 1H), 5.25 (d, J = 9.9 Hz, 1H), 5.12 (dd, J = 3.9, 5.7 Hz, 1H), 5.05-4.90 (m, 1H), 4.11 (dd, J = 3.9, 13.2 Hz, 1H), 4.02-3.88 (m, 3H), 2.21-2.06 (m, 1H), 1.49 (ddd, J = 2.4, 4.5, 14.1 Hz, 1H), 1.31 (d, J = 6.9 Hz, 3H).
Example 3j
Under carbon mono-oxide atmosphere, a mixture of 25.0 g of compound 10, 11.6g of /- Pr2NEt1 12.8 g of 2,4-difluorobenzylamine, 335 mg of Pd(OAc)2 and 1.9 g of 1 ,4- bis(diphenylphosphino)butane in 188 mL of DMA was stirred at 85°C for 4 h. After cooling, the reaction mixture was devided and 10/25 of mixture was used for next step. 6.6 g of AcOEt1 29.9 g of water and 3 mg of seed crystal were added to the reaction mixture at 40 0C. After stirring for 7min, 29.9 g of water was added and cooled to room temperature. The crystal was filtered at room temperature and washed by 47.2 g of ethanol to give 10.1 g of compound 11 (83% yield) as a crystal.
1H NMR(300 MHz, CDCI3) δ 10.40 (t, J = 6.0 Hz, 1H), 8.35 (s, 1H), 7.66-7.58 (m, 2H), 7.42-7.24 (m, 5H), 6.78-6.74 (m, 2H), 5.30 (d, J = 9.9 Hz1 1H), 5.26 (d, J = 10.2 Hz, 1H), 5.15 (dd, J = 3.9, 5.7 Hz1 1H)1 5.05-4.90 (m, 1H), 4.64 (d. J = 5.4 Hz, 2H)1 4.22 (dd, J = 3.9, 13.5, 1 H), 4.09 (dd, J = 6.0, 13.2 Hz, 1H), 4.02-3.88 (m, 2H), 2.24-1.86 (m, 1H), 1.50 (ddd, J = 2.4, 4.5, 14.1 Hz, 1H)1 1.33 (d, J = 7.2 Hz, 3H).
Example 3k
Under hydrogen atmosphere, a mixture of 4.0 g of compound 11 and 0.8g of 50% wet 5%
Pd-C in 67.6 mL of THF and 1.6 ml_ of H2O was stirred for 1.5 h at 500C. After mixture of 80mg of NaHSO3 and 2.OmL of purified water was added to the reaction mixture and the reaction mixture was stirred for 1h, precipitate was filtered, washed with 20 mL of THF, and the filtrate was concentrated to 11.97g. After adding 6.7mL of ethanol and 33.6mL of purified water over 1h, reaction mixture was cooled to 250C. Filtration, washing with 26.9mL of EtOH and drying provided 2.33 g of compound 12 (82% yield) as a crystal. 1H NMR(300 MHz1 DMSO-d6) δ 12.51 (S1 1H), 10.36 (t, J = 5.7 Hz, 1 H), 8.50 (s, 1H), 7.39 (td, J = 8.7, 6.3 Hz1 1H), 7.24 (ddd, J = 2.6, 9.5, 10.8 Hz, 1H), 7.12-7.00 (m, 1H), 5.44 (dd, J = 3.9, 5.7 Hz, 1 H), 4.90-4.70 (m, 1 H), 4.65-^.50 (m, 1 H), 4.54 (d, J = 5.1 Hz, 2H), 4.35 (dd, J = 6.0, 13.8 Hz, 1H), 4.10-3.98 (m, 1H), 3.96-3.86 (m, 1H), 2.10-1.94 (m, 1H), 1.60-1.48 (m, 1H), 1.33 (d, J = 6.9 Hz, 3H).
Example 3I
After dissolution of 18.O g of compound 12 (1.0 eq.) in 54 mL of EtOH by heating, followed by filtration, 21.5 mL of 2N NaOHaq.(1.0 eq.) was added to the solution at 80 °C. The solution was gradually cooled to room temperature. Filtration, washing with 80 mL of EtOH and drying provided 18.8 g of compound 13 (99% yield) as a crystal.
1H NMR(300 MHz, DMSO-Cf6) δ 10.70 (t, J = 6.0 Hz, 1H), 7.89 (s, 1H)1 7.40-7.30 (m, 1H)1 7.25-7.16 (m, 1H)1 7.06-6.98 (m, 1H), 5.22-5.12 (m, 1H), 4.87-4.74 (m, 1H), 4.51 (d, J = 5.4 Hz, 2H), 4.35-4.25 (m, 1H), 4.16 (dd, J = 1.8, 14.1 Hz, 1H), 4.05-3.90 (m, 1H), 3.86- 3.74 (m, 1H), 2.00-1.72 (m, 1H)1 1.44-1.32 (m, 1H), 1.24 (d, J = 6.9 Hz1 3H).
Apparatus and conditions used to generate Figures 1 - 7 are as follows: Measurement of X-ray Powder Diffraction Pattern The measuring conditions used were the same as general metrology for the X-ray powder diffraction pattern measurement described in "The Japanese Pharmacopoeia Fifteenth Edition".
Measuring apparatus RINT TTR III Methods
The acquisition conditions were as follows. Measurement Method: parallel beam method Tube anode: Cu Radiation: Cu Ka
Generator current: 300 mA
Generator tension: 50 kV
The sample was prepared on an aluminum wafer
Angle of incidence: 4°and 40°
Measurement of infrared spectroscopy analysis
The acquisition conditions used for were as follows.
Measuring apparatus
FT/IR-4200typeA (by JASCO Corporation) Methods
Measurement method: ATR (Attenuated total reflection) method
Resolution: 4 (cm-1)
Detector: DLATGS
Accumulation: 32 times
Measurement of solid-state 13C NMR spectra
The spectrum was obtained using the cross polarization magic-angle-spinning (CP/MAS) method. The acquisition conditions were as follows.
Measuring apparatus Spectrometer: Varian NMR Systems (1 H frequency : 599.8MHz)
Methods
Probe: 3.2mm T3 HX Probe
Spectral width: 43103.4 Hz
Acquisition Time: 0.04s Recycle Delay: 10s
Contact Time: 3ms External standard: adamantane (methyne carbon:38.52ppm) Temperature : 10 MAS rate: 2OkHz
Example A
The starting material of Example A is compound 8, which is identical to formula (Ia). Thus, Example A depicts a process in providing an intermediate for the compound of formula 17 below which is isomeric to the compound ZZ-2 at page 237 of WO 2006/116764 to Brian Johns et al.
Figure imgf000030_0001
14
Figure imgf000030_0002
Figure imgf000030_0003
Example Aa After dissolution of mixture of 320 g of compound 8 (1.0 eq.) in 3.20 L of MeOH by heating, the solution was concentrated. To the residue, 1.66 L of MeCN, 5.72 mL of AcOH(0.1 eq.) and 82.6 g of (S)-2-Amino-propan-1-ol(1.1 eq.) were added and the mixture was heated to 70 °C, stirred at 70 0C for 4 h and concentrated. To the residue, 1.67 L of 2-propanol was added and the mixture was concentrated (twice). After cooling of the residue, filtration, washing with 500 mL of cold 2-propanol and drying provided 167 g of compound 14 (52% yield) as a crystal. 1H NMR(300 MHz1 CDCI3) δ 7.61-7.55 (m, 2H), 7.40-7.20 (m, 4H), 6.53 (d, J = 7.2, 1H), 5.46 (d, J = 10.5 Hz, 1H), 5.23 (d, J = 10.2 Hz, 1H), 5.20 (dd, J = 3.9, 9.6 Hz, 1H), 4.46- 4.34 (m, 1H)1 4.31 (dd, J = 6.6, 8.7 Hz, 1H)1 4.14 (dd, J = 3.9, 12.3 Hz1 1H)1 3.79 (dd, J = 9.9, 12.3 Hz1 1 H), 3.62 (dd, J = 6.9, 8.7 Hz1 1 H), 1.38 (d, J = 6.3 Hz1 3H).
Example Ab
To slurry of 156 g of compound 14 (1.0 eq.) in 780 ml_ of NMP was added 93.6 g of NBS(1.1 eq.) and the mixture was stirred at room temperature for 2.5 h. The reaction mixture was added to 3.12 L of H2O. Filtration, washing with 8.0 L of H2O and drying provided 163 g of compound 15 (84% yield) as a crystal.
1H NMR(300 MHz, DMSO-CT6) δ 8.37 (s, 1H), 7.55-7.50 (m, 2H), 7.42-7.25 (m, 3H), 5.34 (dd, J = 3.6, 9.9 Hz, 1H), 5.18 (d, J = 10.8 Hz, 1H), 5.03 (d, J = 10.5 Hz, 1H), 4.53 (dd, J = 3.6, 12.0 Hz, 1H)1 4.40-4.20 (m, 2H), 3.99 (dd, J = 9.9, 11.7 Hz1 1H), 3.64 (dd, J = 5.7, 8.1 Hz1 1 H)1 1.27 (d, J = 6.3 Hz1 3H).
Example Ac
Under carbon mono-oxide atmosphere, a mixture of 163 g of compound 15 (1.0 eq.), 163 mL of /-Pr2NEt(2.5 eq.), 68.4 ml_ of 2,4-difluorobenzylamine(1.5 eq.) and 22.5 g of Pd(PPh3)4(0.05 eq.) in 816 mL of DMSO was stirred at 90 0C for 7 h. After cooling, removal of precipitate, washing with 50 mL of DMSO and addition of 11.3 g of
Pd(PPh3)4(0.025 eq.), the reaction mixture was stirred at 90 0C for 2 h under carbon mono-oxide atmosphere again. After cooling, removal of precipitate and addition of 2.0 L of AcOEt and 2.0 L of H2O1 the organic layer was washed with 1.0 L of 1 N HCIaq. and 1.0 L of H2O (twice) and the aqueous layer was extracted with 1.0 L of AcOEt. The organic layers were combined and concentrated. Silica gel column chromatography of the residue provided 184 g of compound 16 (96% yield) as foam.
1H NMR(300 MHz, CDCI3) δ 10.38 (t, J = 6.3 Hz1 1H)1 8.39 (s, 1H)1 7.75-7.25 (m, 7H), 6.90-6.70 (m, 2H), 5.43 (d, J = 10.2 Hz, 1H), 5.24 (d, J = 10.2 Hz, 1H)1 5.19 (dd, J = 3.9, 9.9 Hz, 1H)1 4.63 (d, J = 6.0 Hz, 2H), 4.50-4.25 (m, 3H)1 3.86 (dd, J = 9.9, 12.3 Hz, 1H), , 3.66 (dd, J = 6.9, 8.4 Hz1 1 H), 1.39 (d, J = 6.0 Hz, 3H).
Example Ad
Under hydrogen atmosphere, a mixture of 184 g of compound 16 (1.0 eq.) and 36.8 g of 10%Pd-C in 3.31 L of THF and 0.37 L of MeOH was stirred for 3 h. After filtration of precipitate(Pd-C), washing with THF/MeOH(9/1 ) and addition of 36.8 g of 10% Pd-C, the mixture was stirred for 20 min under hydrogen atmosphere. After filtration of precipitate(Pd-C) and washing with THF/MeOH(9/1), the filtrate was concentrated. After 200 ml_ of AcOEt was added to the residue, filtration afforded crude solid of compound 17. The precipitates were combined and extracted with 4.0 L of CHCl3/MeOH(5/1). After concentration of the CHCI3ZMeOH solution and addition of 250 ml_ of AcOEt to the residue, filtration afforded crude solid of compound 17. The crude solids were combined and dissolved in 8.2 L of MeCN/H2O(9/1 ) by heating. After filtration, the filtrate was concentrated. To the residue, 1.5 L of EtOH was added and the mixture was concentrated (three times). After cooling of the residue, filtration and drying provided 132 g of compound 17 (88% yield) as a crystal. 1H NMR(300 MHz, DMSO-cfe) δ 11.47 (brs, 1H), 10.31 (t, J = 6.0 Hz, 1H), 8.46 (s, 1H), 7.40 (td, J = 8.6, 6.9 Hz, 1H), 7.24 (ddd, J = 2.6, 9.4, 10.6, 1H), 7.11-7.01 (m, 1H), 5.39 (dd, J = 4.1, 10.4 Hz, 1H), 4.89 (dd, J = 4.2, 12.3 Hz, 1H), 4.55 (d, J = 6.0 Hz, 2H), 4.40 (dd, J = 6.8, 8.6 Hz, 1H), 4.36-^.22 (m, 1H)1 4.00 (dd, J = 10.2, 12.3 Hz, 1H), 3.67 (dd, J = 6.7, 8.6 Hz, 1H), 1.34 (d, J = 6.3 Hz, 3H).
Example Ae
After dissolution of 16.0 g of compound 17 (1.0 eq.) in 2.56 L of EtOH and 0.64 L of H2O by heating, followed by filtration, 39 ml_ of 1N NaOHaq.(1.0 eq.) was added to the solution at 75 0C. The solution was gradually cooled to room temperature. Filtration, washing with 80 ml_ of EtOH and drying provided 13.5 g of compound 18 (80% yield) as a crystal.
1H NMR(300 MHz, DMSO-cfe) δ 10.73 (t, J = 6.0 Hz, 1H), 7.89 (s, 1H), 7.40-7.30 (m, 1H), 7.25-7.16 (m, 1H), 7.07-6.98 (m, 1H), 5.21 (dd, J = 3.8, 10.0 Hz, 1H), 4.58 (dd, J = 3.8, 12.1 Hz, 1H), 4.51 (d, J = 5.4 Hz, 2H), 4.3CM.20 (m, 2H), 3.75 (dd, J = 10.0, 12.1 Hz, 1H), 3.65-3.55 (m, 1H), 1.27 (d, J = 6.1 Hz, 3H).
Example B
This Example B utilizes a process to insert a ring nitrogen in place of oxygen in a pyrone ring and create an aldehyde equivalent by an osmium oxidation of a double bond. Thus, this example is not a bromination of the invention.
Figure imgf000033_0001
Figure imgf000033_0002
DMSO
H
Figure imgf000033_0003
I
Example Ba
To a bromobenzene (238 ml) solution of compound A (23.8 g, 110 mmol), selene dioxide
(24.4 g, 220 mmol) was added. The reaction mixture was stirred for 13 hours at 140 0C with removing water by Dean-Stark trap. Insoluble particles were removed by filtration after cooling, and solvent was evaporated. Toluene was added to the residue and precipitates were filtered off. After concentration in vaccuo, the residue was purified by silica gel column chromatography (hexane / ethyl acetate). Compound B (16.5 g, 65%) was obtained as yellow oil.
1H-NMR (CDCI3) δ: 5.51(2H, s), 6.50(1H1 d, J=5.4Hz), 7.36(5H, s), 7.75(1 H, d, J=5.4Hz),
9.88(1H, s). Example Bb
To an ice cooled aqueous (465 ml) solution of sodium chlorite (38.4 g, 424 mmol) and sulfamic acid (54.9 g, 566 mmol), acetone (465 ml) solution of compound B (46.5 g, 202 mmol) was added and the mixture was stirred for 40 minutes at room temperature. After removing acetone in vaccuo, precipitates were collected by filtration and washed with cold water. Compound C (42.8 g, 86%) was obtained as colorless crystal.
1H-NMR(DMSO-d6) δ: 5.12(2H, s), 6.54(1 H, d, J=5.6Hz), 7.33-7.46(5H, m), 8.20(1 H, d,
J=5.6Hz).
Example Bc
An ethanol (17 ml) solution of allylamine (13.2g 231 mmol) was added to an ethanol (69 ml) suspension of compound C (17.2 g, 70 mmol), then the mixture was stirred for 4.5 hours at 500C and for 3 hours at 750C. To the cooled reaction mixture, 2N hydrochloric acid and ice were added and precipitates were collected by filtration. Compound D was obtained as colorless crystal.
1H-NMR(CDCI3) δ: 4.37(2H, brs), 4.95(2H, s), 5.26-5.39(2H, m), 5.81-5.94(1 H, m),
6.32(1H1 dd, J=0.8, 7.2Hz), 7.29-7.37(3H, m), 7.48-7.51 (2H, m), 7.99(1 H, dd, J=0.8,
7.6Hz), 8.11(1H, brs).
Example Bd
To an acetonitrile (146 ml) suspension of compound D (14.6 g, 51 mmol), 1 ,8- diazabicyco[5.4.0]undec-7-ene (15.5 g, 102 mmol) and methyl iodide (18.2 g, 128 mmol) were added and the mixture was stirred for 15 hours at room temperature. After evaporating solvent, the residue was purified by silica gel column chromatography
(chloroform / methanol). Compound E (14.2 g, 93%) was obtained as colorless solid.
1H-NMR(CDCI3) δ: 3.75(3H, s), 4.40(2H, d, J=5.7Hz), 5.16-5.35(2H, m), 5.29(2H, s), 5.81-
5.94(1 H, m), 6.62(1 H, d, J=7.5Hz), 7.27-7.42(6H, m).
Example Be
To a diethyl ether (390 ml) solution of compound E (13.3 g, 44 mmol), potassium osmate(VI) dihydrate (1.62 g, 4.4 mmol) and sodium metaperiodate (28.1 g, 132 mmol) were added. The mixture was stirred for 2.5 hours at room temperature and precipitates were collected by filtration. Collected solid was dissolved in chlorofoπm-methanol and insoluble particles were filtered off. Concentration in vaccuo gave crude product of compound F (14.3 g). 1 H NMR (DMSO-d6) δ: 3.23 (3H, s), 3.82 (3H, s), 3.87 (2H, t, J= 4.4Hz), 4.62 (1 H, dd, J=11.7, 4.8 Hz), 5.11 (2H, s), 6.31 (1H1 d, J= 7.5 Hz), 6.78 (1H1 d, J= 6.6 Hz)1 7.33-7.40 (5H, m), 7.64 (1H, d, J= 7.5 Hz).
Example Bf
To chloroform (108 ml) and methanol (12 ml) solution of compound F (11.7 g, crude product), 3-aminopropanol (2.77g, 36.9 mmol), and acetic acid (1.2 ml) were added and the mixture was stirred for 90 minutes at 700C. After concentrating in vaccuo, the residue was purified by silica gel column chromatography (chloroform / methanol). Compound G (8.48 g, 72% for 2 steps) was obtained as colorless cryatal.
1H-NMR(CDCI3) δ: 1.54-1.64(1 H, m), 1.85-2.01(1 H, m), 3.00(1H, dt, J=3.6, 12.9Hz), 3.74(1H, dt, J=2.7, 12.3Hz), 3.93(1H, dd, J=5.1 , 13.5Hz), 4.07-4.21(2H, m), 4.63^.69(1H, m), 4.94(1 H, t, J=4.8Hz), 5.25(2H, dd, J=10.2, 24.6Hz), 6.56(1 H, d, J=7.5Hz), 7.22- 7.38(5H, m), 7.63-7.66(2H, m).
Example Bg
To acetic acid (93 ml) solution of compound G (6.1 g, 18.7 mmol), acetic acid (31 ml) solution of bromine (1.44 ml, 28.0 mmol) was added dropwisely during 15 minutes. The mixture was stirred for 3 hours at room temperature. After addition of 5% aqueous sodium hydrogen sulfite (8 ml), 2N sodium hydroxide (500ml) was added dropwisely during 20 minutes. Precipitates were collected by filtration and washed with mixture of dichloromethane and diisopropyl ether. Compound H (6.02 g, 79%) was obtained as colorless crystal. 1H-NMR(DMSO-Cf6) δ: 1.55-1.74(2H1 m), 3.12(1H, dt, J=3.0, 12.3Hz), 3.84(1H, dt, J=2.7, 11.7Hz), 4.00-4.05(1H, m), 4.20-4.26(1 H, m), 4.40-4.46(2H, m), 5.03(2H, s), 5.15- 5.17(1H, m), 7.31-7.40(3H, m), 7.56-7.58(2H, m), 8.39(1 H, s).
Example Bh
To dimethyl sulfoxide (1.42 ml) solution of compound H (71 mg, 0.175 mmol) and tetrakis(triphenylphosphine)palladium(0) (25 mg, 0.035 mmol), 4-fluorobenzyl amine (0.06 ml, 0.525 mmol) and diisopropyl amine (0.15 ml, 0.875 mmol) were added, then the mixture was stirred under carbon monoxide atmosphere for 5 hours at 80 0C. After cooling, saturated aqueous ammonium chloride was added and the mixture was extracted with ethyl acetate. The extract was washed with water and dried with anhydrous sodium sulfate. Solvent was removed in vaccuo and the residue was purified with silica gel column chromatography (ethyl acetate / methanol). Compound I (74.5 mg, 89%) was obtained as colorless crystal.
1H-NMR(DMSOd6) δ: 1.58-1.74(2H, m), 3.10-3.18(1H, m), 3.80-3.88(1H, m), 4.02- 4.07(1H1 m), 4.43-4.59(5H, m), 5.05(2H, s), 5.20(1H1 1, J=3.9Hz), 7.13-7.19(2H1 m), 7.32- 7.40(5H, m), 7.56-7.59(2H, m), 8.61 (1 H, s).
Example C
Synthesis of methyl 5-bromo-1-[2-hydroxy-2-(methyloxy)ethyl]-4-oxo-3- [(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate (in equillibrium with the corresponding aldehyde)
This Example C shows a refunctionalization of a compound 6 as shown above in Example 1 (of formula (Vl)), including a bromination at the R* position, to yield final products 20 and 21 (of formula (I)). Such compounds with Br at the Rx position can be reacted as in Examples 1 and 2 to add the R2-X-NR1-C(O)- sidechain.
Figure imgf000036_0001
6 7
19
Figure imgf000036_0002
20 21
Example Ca
Methyl 1 -(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2- pyridinecarboxylate
Figure imgf000037_0001
A reactor was charged with 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4- dihydro-2-pyridinecarboxylic acid 6 (4.302 kg, 13.47 mol) followed by charging with NaHCO3 (1.69 kg, 20.09 mol) and 242 g of deionized water. To this was added 21.4 kg of NMP and the mixture was stirred and temperature brought to 28-350C. Dimethyl sulfate (2.34 kg, 18.30 mol) was added dropwise via an addition funnel to the reaction mixture over 1-3 hours keeping the temperature at 28-33 0C. The slurry was agitated at this temperature for 14 h. When deemed complete, the reaction mixture was cooled to 5 0C or below and the mixture was neutralized to pH 6 by the addition of HCI (561 mL of cone HCI in 2806 g of deionized water). The reaction vessel was slowly charged with cold 20% brine solution composed of 8.7 kg NaCI, 20 kg of deionized water and 14.8 kg of ice at a maximum temperature of 100C. The mixture was agitated at 0-100C for 2.5 h. The slurry was filtered under vacuum and the cake washed with 15 kg of deionized water two times. The wet solid product was dried at 45-55 0C under vacuum until constant weight was obtained. The desired product methyl 1-(2,3-dihydroxypropyl)-4-oxo-3- [(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylate 7 was obtained as a light yellow solid (3.77 kg, 99.42% purity by HPLC1 84%). 1H NMR(300 MHz, DMSO-d6) δ 7.60 (d, J = 7.5 Hz, 1 H), 7.36 (m, 5 H), 6.28 (d, J = 7.5 Hz, 1 H), 5.23 (d, J = 5.4 Hz, 1 H), 5.10 (Abq, J = 10.8 Hz, 2 H), 4.85 (m, 1 H), 3.98 (dd, J = 14.3, 2.4 Hz, 1 H), 3.79 (s, 3 H), 3.70 (dd, J = 14.3, 9.0 Hz, 1 H), 3.58 (m, 1 H), 3.23 (m, 1 H).
Example Cb
Methyl 5-bromo-1 -(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2- pyridinecarboxylate.
Figure imgf000038_0001
19
A reactor was charged with (3.759 kg, 11.27 mol) of methyl 1-(2,3-dihydroxypropyl)-4-oxo- 3-[(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylate 7 and 18.8 L of DMF. To this agitated mixture at 18-200C was added N-bromosuccinimide (2.220 kg, 12.47 mol) over 20 minutes via a powder funnel. The resultant mixture was stirred at rt for 16 h. At this time less than 1% of starting material was present by HPLC. The mixture was worked up in half batches by cooling to 100C and added an ice/water mixture (12 kg ice in 35 kg deionized water) and the mixture was agitated, then filtered. This was repeated for the second half of the batch. The combined filter cake was washed with 14 L of water and dired in a vaccum oven to provide 4.033 kg of methyl 5-bromo-1-(2,3-dihydroxypropyl)-4- oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate 19 (91.6%) as an off-white powder of 99.2% HPLC purity. 1H NMR(300 MHz, Methanol-d4) δ 8.21 (s, 1 H), 7.41-7.33 (m, 5 H)1 5.16 (s, 2 H), 4.17 (dd, J = 14.3, 2.4 Hz, 1 H), 3.90 (dd, J = 14.3, 9.0 Hz, 1 H), 3.81 (S, 3 H), 3.78 (m, 1 ), 3.52 (dd, J = 11.3, 4.8 Hz, 1 H), 3.41 (dd, J = 11.3, 6.3 Hz, 1 H).
Example Cc
Methyl 5-bromo-1 -[2-hydroxy-2-(methyloxy)ethyl]-4-oxo-3-[(phenylmethyl)oxy]-1 ,4- dihydro-2-pyridinecarboxylate (in equilibrium with the corresponding aldehyde)
Figure imgf000038_0002
19 21
20
A reactor was charged with sodium periodate (1.67 kg, 7.8 mol) and 44 L of deionized water. To the agitated mixture was added 8.5 kg of ice. This was stirred until all the ice melted and the mixture temperature was 1.40C. To this was added methyl 5-bromo-1- (2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylate 19 (2.73 kg, 6.62 mol) via a powder addition funnel. The mixture was allowed to warm to rt and the slurry was stirred for 16 h. A sample was monitored by 1H NMR and showed the disappearance of starting material. The mixture was filtered and the cake washed with 20 kg of deionized water. This was repeated until a negative starch/iodide paper result was obtained (4X20 L washes). The solids were dried in a vaccum oven at 45-550C to provide methyl 5-bromo-1-(2,2-dihydroxyethyl)-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2- pyridinecarboxylate 20 (2.176 kg, 88%) as a mixture with the corresponding aldehyde form 21. Purity was determined to be 99.5% by HPLC. 1H NMR(300 MHz, acetone-d6) δ 8.12 (S, 1 H), 7.49-7.30 (m, 5 H), 5.56 (dd, J = 6.0, 2.4 Hz, 1 H), 5.23 (m, 1 H), 5.20 (s, 2 H), 3.97 (d, J = 5.1 Hz, 2 H), 3.87 (s, 3 H).
Example 2 Methyl 5-({[(2,4-difluorophenyl)methyl]amino}carbonyl)-1 -[2-hydroxy-2-(methyloxy)ethyl]- 4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylate (in equilibrium with the corresponding aldehyde)
This Example shows a reaction of a compound 5 of formula (II) with one of (III) in step i) and a refunctionalization step ii) of compounds of formula (V) (compounds 22, 23, 24 and 25) in producing compounds of formula (I).
Figure imgf000040_0001
22
Figure imgf000040_0002
26 27
Example 2a 1-[2,2-Bis(methyloxy)ethyl]-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylic acid
Figure imgf000040_0003
22
To a flask (1 L) charged with 500 ml. of anhydrous ethanol was added 49.2g (0.2 mol) of 4-oxo-3-[(phenylmethyl)oxy]-4H-pyran-2-carboxylic acid 5. The suspension was slowly heated to 55-600C before addition of 2-amino-acetaldehyde-dimethylacetal (84.1g, 0.8 mole). The reaction was then brought up to 65 0C and further stirred for 18 hours. The solvent was removed under reduced pressure to produce 1-[2,2-Bis(methyloxy)ethyl]-4- oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylic acid 22 (crude) as brown oil, which was used for the next step directly. Example 2b
Methyl 1 -[2,2-bis(methyloxy)ethyl]-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2- pyridinecarboxylate
Figure imgf000041_0001
22 23
Crude 1 -[2,2-bis(methyloxy)ethyl]-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2- pyridinecarboxylic acid 22 obtained as above was dissolved in DMF (500 ml_). To this solution was added NaHCO3 (50.5g, 0.6 mole). The suspension was stirred vigorously with a mechanic stirrer while CH3I in TBME (2.0 M, 300 mL) was introduced by addition funnel over 30 minutes. After addition, the reaction was stirred overnight at room temperature. The reaction mixture was then diluted with EtOAc (~1.5L) and washed with water and brine. The organic layer was dried over anhydrous Na2SO4. Evaporation of solvents gave methyl 1 -[2,2-bis(methyloxy)ethyl]-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro- 2-pyridinecarboxylate 23 as brown oil, which was used directly for the next step.
Example 2c
Methyl 1 -[2,2-bis(methyloxy)ethyl]-5-bromo-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2- pyridinecarboxylate
Figure imgf000041_0002
23 24
A 2L flask equipped with a mechanic stirrer were charged with methyl 1-[2,2- bis(methyloxy)ethyl]-4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylate 23 as obtained above and 500 mL of dichloromethane. To this flask was added NBS (30 g,
0.17mole) portion-wise. The reaction was stirred at room temperature until its completion (monitored by TLC, ~6 hours). The mixture was then diluted with dichloromethane and washed with NaHCO3 (ss). The organic phase was dried over Na2SO4 before evaporation of the solvents. The crude product was purified by column chromatargraphy ( silcal gel, EtOH/DCM: 0-40%) to afford methyl 1-[2,2-bis(methyloxy)ethyl]-5-bromo-4-oxo-3- [(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylate 24 as a light brown solid (5Og, 60 % over three steps). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.7 (s, 1 H), 7.4 (m, 2 H), 7.3 (d, J=7.9 Hz, 3 H), 5.3 (s, 2 H), 4.4 (s, 1 H), 3.8 (d, J=4.8 Hz, 2 H), 3.8 (s, 3 H), 3.4 (s, 6 H). LC-MS (M+H+): calcd 426, obsd 426.
Example 2d
Methyl 1-[2,2-bis(methyloxy)ethyl]-5-({[(2,4-difluorophenyl)methyl]amino}carbonyl)-4-oxo- 3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate
Figure imgf000042_0001
24 25
A pressure vessel was charged with methyl 1-[2,2-bis(methyloxy)ethyl]-5-bromo-4-oxo-3- [(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate 24 (6.4g, 15 mmol), 2,4- difluorobenzylamine (3.2g, 22.5 mmol), K3PO4 (9.45g, 45mmol), Pd(OCOCF3J2 (398mg, 1.2 mmol), Xantophos (694mg, 1.2 mmol) and toluene (200 mL). The mixture was purged by CO (4X) before being heated to 1000C for 22 hours under CO atmosphere (60psi). After cooled down to the room temperature, the solids were filtered off through celite and washed with EtOAc. The filtrate was concentrated and the residual was purified by column chromatography ( silical gel, EtOAc/hexane 0-80%) to afford methyl 1-[2,2- bis(methyloxy)ethyl]-5-({[(2,4-difluorophenyl)methyl]amino}carbonyl)-4-oxo-3- [(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate 25 as a light brown oil (4.7g, 61%). 1H NMR (400 MHz1 CHLOROFORM-cQ δ ppm 10.4 (m, 1 H), 8.4 (s, 1 H), 7.4 (m, 6 H)1 6.8 (d, J=9.3 Hz, 2 H), 5.3 (s, 2 H), 4.6 (d. J=5.7 Hz, 2 H)1 4.5 (s. 1 H), 4.0 (d, J=4.8 Hz, 2 H), 3.8 (S1 3 H)1 3.4 (S1 6 H). LC-MS (M+H+): calcd 517, obsd 517.
Example 2e Methyl 5-({[(2,4-difluorophenyl)methyl]amino}carbonyl)-1-[2-hydroxy-2-(methyloxy)ethyl]- 4-oxo-3-[(phenylmethyl)oxy]-1 ,4-dihydro-2-pyridinecarboxylate (in equilibrium with the corresponding aldehyde)
Figure imgf000043_0001
25 26 27
Methyl 1-[2,2-bis(methyloxy)ethyl]-5-({[(2,4-difluorophenyl)methyl]amino}carbonyl)-4-oxo- 3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate 25 (11.6 g ) was treated with 90% formic acid (250 mL) at 40 0C for -12 hours (monitored by LC-MS). After the solvents were evaporated at <40 0C1 the residue was re-dissolved in EtOAc (~ 1 L) and the resulting solution was washed with NaHCO3 and brine. The organic phase was then dried over Na2SO4. After evaporation of solvents, the titled compounds 26 and 27 were obtained as an approximate 80/20 equillibrium mixture (10.57g). 1H NMR (400 MHz1 DMSO-d6) δ ppm 10.3 (m, 1 H), 9.47 (s, aldehyde-H. -0.2 H)), 8.4 (m, 1 H)1 7.3 (s, 6 H), 7.2 (m, 1 H), 7.0 (m, 1 H), 6.3 (m, 2 H), 5.1 (s, 3 H)1 4.9 (m, 1 H)1 4.5 (m, 3 H), 3.9 (m, 2 H), 3.8 (s. 3 H). LC-MS1 for 26 (M+H+), calcd 503, obsd 503; for 27 (M+H2O+H+), cald 489, obsd 489.
Example CC
(4aS, 1 SaflHV-P^-DifluorophenyOmethylH O-hydroxy-9, 11 -dioxo-2,3,4a,519, 11 , 13, 13a- octahydro-1 H-pyrido[1 ,2-a]pyrrolo[1 ',2':3,4]imidazo[1 ,2-c(]pyrazine-8-carboxamide.
Figure imgf000044_0001
Example CCa: (4aS, 13a/?)-8-Bromo-10-[(phenylmethyl)oxy]-2,3,4a,5, 13,13a-hexahydro- 1 H-pyrido[1 ,2-a]pyrrolo[1 ',2':3,4]imidazo[1 ,2-Gflpyrazine-9, 11 -dione (DD). A reactor was charged with [(2f?)-2-pyrrolidinylmethyl]amine (0.75 kg) and 4.6 L of DMF was added followed by 0.45 kg of glacial acetic acid. Acetonitrile (41.4 L) was then added and the mixture was agitated for 15 minutes. To the reaction mixture was added methyl 5- bromo-1-(2,2-dihydroxyethyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2- pyridinecarboxylate (2.30 kg). After stirring for 20 minutes at ambient temperature, the mixture was heated at 75-850C until the bromide starting material was consumed by HPLC analysis (about 6 hrs). Upon completion, the mixture was cooled until the refluz subsided and then charged with 6.9 L of methanol and the mixture was heated at reflux for about 45 minutes then cooled to 15 0C and filtered and dried to provide (4aS,13af?)-8- bromo-10-[(phenylmethyl)oxy]-2,3,4a,5,13,13a-hexahydro-1H-pyrido[1,2- a]pyrrolo[1',2':3,4]imidazo[1,2-c(lpyrazine-9,11-dione (1.93 kg, 78%) as a white solid. ). 1H NMR (300 MHz, DMSO-Cf6) δ ppm 8.65 (m, 1 H), 7.54 (m, 2 H), 7.33 (m, 3 H), 5.15 (d, 1 H), 4.99 (d, 1 H), 4.60 (m, 1 H), 4.36 (m, 1 H), 4.03 (m, 1 H), 3.90 (m, 1 H), 3.65 (m, 1 H), 3.06-2.84 (m, 3 H), 1.92-1.60 (m, 4 H).
Example CCb: (4aS,13aR)-Λ/-[(2,4-Difluorophenyl)methyl]-9l11-dioxo-10- [(phenylmethyl)oxy]-2,3,4a,5,9,11 ,13,13a-octahydro-1 A7-pyrido[1 ,2- a]pyrrolo[1',2':3,4]imidazo[1,2-cdpyrazine-8-carboxamide. A reaction vessel was charged with (4aS, 13af?)-8-bromo-10-[(phenylmethyl)oxy]-2,3,4a,5, 13, 13a-hexahydro-1 H- pyridoII^-alpyrroloti'.Σ'^^limidazoli.Z-cdpyrazine-θ.i i-dione (1.4 kg), 2,4- difluorobenzylamine (705 g), Hunigs base (1.4L), dppf (60 g) and DMSO (12 L). The mixture was degassed with high purity nitrogen 4 times. To this mixture was added palladium (II) trifluoroacetate (18 g) in DMSO (2L). The mixture was again degassed 3 times with high purity nitrogen and then purged with CO 3 times and left under a 45 psi atmosphere of CO. The mixture was heated at 800C under 45 psi CO until the reaction appeared complete by HPLC (24 hrs). The mixture was cooled to rt and slowly transferred to an ice slurry of ammonium chloride. The mixture was filtered and washed with water and isopropanol. The residue was recrystallized from isopropanol to provide (4aS, 13af?)-Λ/-[(2,4-Difluorophenyl)methyl]-9, 11 -dioxo-10-[(phenylmethyl)oxy]-
2,3,4a,5,9, 11 , 13,13a-octahydro-1 H-pyrido[1 ,2-a]pyrrolo[1 ',2':3,4]im\dazo['\ ,2-cGpyrazine-8- carboxamide (952 g, 56%). Recrystallization of the mother liquor from isopropanol produced a second crop of crystals of the desired product in the amount of 327 g (19%). 1H NMR (300 MHz, DMSO-cfe) δ ppm 10.44 (m, 1 H), 8.55 (s, 1 H), 7.56-7.07 (m, 8 H), 5.18 (d, 1 H)1 5.03 (d, 1 H), 4.62-4.54 (m, 4 H), 4.06-3.60 (m, 3 H), 3.20-2.80 (m, 3 H), 1.93-1.60 (m, 4 H).
Example CCc: (4aS,13af?)-Λ/-[(2,4-Difluorophenyl)methyl]-10-hydroxy-9,11-dioxo- 2,3,4a,5,9, 11,13,13a-octahydro-1 H-pyrido[1 ,2-a]pyrrolo[1 l,2I:3,4]imidazo[1 ,2-d]pyrazine-8- carboxamide. A pressure reaction vessel was charged with (4aS,13af?)-Λ/-[(2,4- Difluorophenyl)methyl]-9, 11 -dioxo-10-[(phenylmethyl)oxy]-2,3,4a,5,9, 11 , 13, 13a- octahydro-1 H-pyrido[1 ,2-a]pyrrolo[1 ',2':3,4]imidazo[1 ,2-c/]pyrazine-8-carboxamide (950 g), 192 g of palladium on carbon (50% wet), ethanol (9.5 L) and concentrated ammonium hydroxide (124 mL). The mixture was degassed with nitrogen 3 times and then placed under 50 psi of hydrogen until the reaction was complete. The mixture was degassed again with nitrogen and then filtered through Celite. The cake was extracted with refluxing dichloromethane and then filtered again. The combined filtrates were concentrated to a small volume (4L), azeotroped with ethanol (28.5L) to a final volume of 9 L. The slurry was filtered and washed with ethanol and dried to produce (4aS,13aR)-Λ/-[(2,4- difluorophenyl)methyl]-10-hydroxy-9,11-dioxo-2,3I4aI5,9,11,13,13a-octahydro-1H- pyridoII.Σ-alpyrrolofr^'rS^limidazoII ^-cdpyrazine-δ-carboxamide (616 g, 78.4%) as a white solid. 1H NMR (300 MHz, DMSO-Cf6) δ ppm 10.37 (m, 1 H), 8.42 (s, 1 H), 7.41-7.05 (m, 3 H), 4.72-4.53 (m, 4 H), 4.05(m, 1 H), 3.86 (m, 1 H), 3.70 (m, 1 H), 3.16 (m, 1 H), 2.88 (m, 2 H), 1.92-1.60 (m, 4 H).

Claims

What is Claimed is:
1. A process of for the preparation of a pyridone compound of formula (AA), (BB) or (CC):
Figure imgf000046_0001
Figure imgf000046_0002
Figure imgf000046_0003
comprising the steps of:
P-1) brominating a compound of the following formula (l-l) to produe a bromine compound of the following formula (M-M):
Figure imgf000046_0004
l-l IMI
wherein R is -CHO, -CH(OH)2, -CH(OH)(OR4), -CH(OH)-CH2OH or - CH(OR5XOR6);
P1 is H or a hydroxyl protecting group;
P3 is H or a carboxy protecting group;
R4 is lower alkyl;
Rs and R6 are independently lower alkyl or R5 and R6 can be alkyl and joined to form a 5-, 6-, or 7-membered ring, and
P-2) creating the 2,4-di-fluorophenyl-CH2-NH-C(O)- sidechain with the reactants
2,4-di-fluorophenyl-CH2-NH2 and carbon monoxide.
2. A process is provided for the preparation of a pyridone compound of the following formula (AA), (BB) or (CC):
Figure imgf000047_0001
Figure imgf000047_0002
Figure imgf000047_0003
comprising the steps of:
P-1) brominating a compound of the following formula (l-l) to produce a bromine compound of the following formula (M-Il):
Figure imgf000048_0001
l-l
wherein
R is -CHO, -CH(OH)2, -CH(OH)(OR4), -CH(OH)-CH2OH or -CH(OR5KOR6);
P1 is H or a hydroxyl protecting group; P3 is H or a carboxy protecting group; R4 is lower alkyl;
R5 and R6 are independently lower alkyl or Rs and R6 can be lower , alkyl and joined to form a 5-, 6-, or 7-membered ring,
P-2) creating the 2,4-di-fluorophenyl-CH2-NH-C(O)- sidechain with the reactants 2,4-di-fluorophenyl-CH2-NH2 and carbon monoxide to form a compound of formula III-
Figure imgf000048_0002
P-3) condensing and debenzylating a compound of formula lll-lll to form a compound of formula AA, BB1 or CC.
The process according to claim 1 , wherein said step P-2) is carried out before creation of the Q ring.
4. The process according to claim 1 or 2, wherein said pyridone compound is of the formula AA.
5. The process according to claim 1 or 2, wherein said pyridone compound is of the formula BB. 6. The process according to claim 1 or 2, wherein said pyridone compound is of the formula CC.
7. The process according to claim 1 , wherein said step P-2) is carried out after creation of the Q ring.
8. The process according to claim 7, wherein said pyridone compound is of the formula AA.
9. The process of Claim 7, wherein said pyridone compound is of the formula BB.
10. The process of Claim 7, wherein said pyridone compound is of the formula CC.
11. A compound of the following formula (DD):
Figure imgf000049_0001
wherein P1 is H or a carboxy protecting group.
12. The compound of claim 11 , wherein P1 is benzyl.
13. A process according to any of claims 1-10 wherein P1 is benzyl; P3 is methyl; and R is -CHO, -CH(OH)(OR4), -CH(OR5J(OR5) wherein R4 and R5 are lower alkyl.
14. A salt or a hydrate thereof of a compound of formula AA
Figure imgf000049_0002
15. A crystal form of a sodium salt or a hydrate thereof of a compound of formula AA
Figure imgf000050_0001
16. A crystal form according to claim 15 having one or more physical properties selected from the group consisting of (i) and (ii):
(i) having characteristic diffraction peaks at 6.4° ± 0.2°, 9.2° ± 0.2°, 13.8° ± 0.2°, 19.2° ± 0.2° and 21.8° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern; and (ii) having characteristic infrared absorption spectra at 1641cm"1 ± 2cm"1, 1536cm"1 ± 2cm" 1 , 1503cm"1 ± 2cm"1 and 1424cm"1 ± 2cm"1.
17. A crystal form according to claim 15 having characteristic diffraction peaks at 6.4° ± 0.2°, 9.2° ± 0.2°, 13.8° ± 0.2°, 19.2° ± 0.2° and 21.8° + 0.2° degrees two-theta in an X- ray powder diffraction pattern.
18. A crystal form according to claim 15 having characteristic diffraction peaks at 6.4° ± 0.2°, 9.2° ± 0.2°, 13.8° ± 0.2°, 14.6° ± 0.2°, 15.2° ± 0.2°, 17.6° ± 0.2°, 19.2° ± 0.2°, 21.8° ± 0.2°, 24.1° ± 0.2° and 28.7° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.
19. A crystal form form according to claim 15 having characteristic infrared absorption spectra at 1641cm"1 ± 2cm"1, 1536cm"1 ± 2cm"1, 1503cm"1 ± 2cm"1 and 1424cm"1 ± 2cm"1.
20. A crystal form according to claim 15 having characteristic infrared absorption spectra at 1641 cm"1 ± 2cm"1 , 1536cm'1 ± 2cm"1 , 1503cm"1 ± 2cm"1 , 1424cm"1 ± 2cm"1 ,
1282cm"1 ± 2cm"1, 1258cm"1 ± 2cm"1, 1093cm"1 ± 2cm"1 and 1069cm"1 ± 2cm"1.
21. A crystal form according to claim 15 having one or more spectra selected from the group consisting of (a) to (c): (a) X-ray powder diffraction pattern substantially as shown in Figure 1 ;
(b) Infrared absorption spectra substantially as shown in Figure 2; and
(c) Solid state 13C-NMR spectra substantially as shown in Figure 3.
22. A crystal form according to claim 15 having one or more physical properties selected from the group consisting of (iii) and (iv): (iii) having characteristic diffraction peaks at 8.0° ± 0.2°, 9.3° + 0.2°, 11.3° ± 0.2°, 16.0° ± 0.2°, and 22.8° ± 0.2°degrees two-theta in an X-ray powder diffraction pattern; and (iv) having characteristic infrared absorption spectra at 1637cm'1 ± 2cm"1, 1536cm'1 ± 2cm" \ 1501cm"1 ± 2cm"1 and 1422cm"1 ± 2cm"1.
23. A crystal form according to claim 15 having characteristic diffraction peaks at 8.0°
± 0.2°, 9.3° ± 0.2°, 11.3° ± 0.2°, 16.0° ± 0.2°and 22.8° ± 0.2° degrees two-theta in an X- ray powder diffraction pattern.
24. A crystal form according to claim 15 having characteristic diffraction peaks at 8.0° ± 0.2°, 9.3° ± 0.2°, 11.3° ± 0.2°, 15.4° ± 0.2°, 16.0° ± 0.2°, 18.7° ± 0.2°, 19.1° ± 0.2°, 19.8° ± 0.2°, 22.8° ± 0.2° and 26.8° ± 0.2" degrees two-theta in an X-ray powder diffraction pattern.
25. A crystal form according to claim 15 having characteristic infrared absorption spectra at 1637cm"1 ± 2cm"1, 1536cm"1 ± 2cm"1, 1501cm'1 ± 2cm"1 and 1422cm"1 ± 2cm"1.
26. A crystal form according to claim 15 having characteristic infrared absorption spectra at 1637cm"1 ± 2cm"1, 1536cm"1 ± 2cm"1, 1501cm"1 ± 2cm"1, 1422cm"1 ± 2cm"1, 1277cm"1 ± 2cm"1 , 1258cm"1 ± 2cm"1 , 1093cm"1 ± 2cm"1 and 1069cm"1 ± 2cm"1.
27. A crystal form according to claim 15 having one or more spectra selected from the group consisting of (d) and (e):
(d) X-ray powder diffraction pattern substantially as shown in Figure 4; and (e) Infrared absorption spectra substantially as shown in Figure 5.
28. A pharmaceutical composition comprising a crystal form as defined in any one of the claims 15 to 27.
29. A process for preparation of a crystal form as defined in any one of the claims 15 to 27.
INTERNATIONAL SEARCH REPORT International application No PCT/US 09/06422
A CLASSIFICATION OF SUBJECT MATTER
IPC(8) - A61 K 31/4412, A61 K 31/351 (2010.01)
USPC - 514/348; 514/432; 514/459; 546/296 According to International Patent Classification (IPC) or to both national classification and IPC
B FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols) IPC(8) A61K 31/4412, A61 K 31/351 (2010 01) USPC 514/348, 514/432, 514/459, 546/296
IPC(8) A61 K 31/4412, A61 K 31/351, A61K 31/44 (201001)
USPC 514/300, 514/348, 514/432, 514/459, 546/296 (text search)
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) PubWEST(USPT,PGPB,EPAB,JPAB), GoogleScholar
Search terms used bromination HIV integrase inhibitory aids immunodeficiency carbamoylpyridone polycyclic fused cyclic tricyclic Yoshida, Taoda, Johns
C DOCUMENTS CONSIDERED TO BE RELEVANT
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No
WO 2006/116764 A1 (JOHNS et al ) 02 November 2006 (02 11 2006), Abstract, page 8 14-29 compound (l-l-l), page 10, para[0017], page 79, line 1, page 79, line 3, page 79, line 4, page 128 compound Z-1 , page 130 compound Z-2, page 113 line 3, page 240 compound (1-7) 1-12
US 6,919,351 B2 (ANTHONY et al ) 19 July 2005 (1907 2005), col 7, In 10, col 53-col 54, 1-12 Scheme 3, col 61-62 Scheme 6
D Further documents are listed in the continuation of Box C D
• Special categories of cited documents "T1 later document published after the international filing date or pπoπty
"A" document defining the general state of the art which is not considered date and not in conflict with the application but cited to und deerr:stand to be of particular relevance the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international "X" document of particular relevance, the claimed invention cannot be filing date considered novel or cannot be considered to involve an inventive
"L" document which may throw doubts on priority claιm(s) or which is step when the document is taken alone cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is
"O" document referring to an oral disclosure, use, exhibition or other combined with one or more other such documents, such combination means being obvious to a person skilled in the art
"P" document published pπor to the international filing date but later than "&" document member of the same patent family the pπoπty date claimed
Date of the actual completion of the international search Date of mailing of the international search report 24 January 2010 (24 01 2010) 12 FEB 2010
Name and mailing address of the ISA/US Authorized officer Mail Stop PCT, Attn ISA/US, Commissioner for Patents Lee W Young P O Box 1450, Alexandria, Virginia 22313-1450
PCT Helpdesk 571-272 4300
Facsimile No 571-273-3201 PCT OSP 571 272 7774
PCT/US2009/006422 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates WO2010068253A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
KR1020177008482A KR101847887B1 (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
MX2013008013A MX351942B (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates.
CN200980149697.6A CN102245182B (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
JP2011540689A JP5086478B2 (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone HIV integrase inhibitors and their intermediates
BRPI0923217A BRPI0923217A2 (en) 2008-12-11 2009-12-08 processes for the preparation of a pyridone compound, and for the preparation of a crystalline form, compound, salt or a hydrate thereof, crystalline form of a sodium salt or a hydrate thereof, and a pharmaceutical composition.
EP09832226.6A EP2376080B1 (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
RU2011121785/04A RU2527451C2 (en) 2008-12-11 2009-12-08 Synthesis of carbamoyl pyridone inhibitors of hiv integrase and intermediate compounds
CA2744019A CA2744019C (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
KR1020117016066A KR101733625B1 (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
MX2011006241A MX2011006241A (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates.
ES09832226.6T ES2641765T3 (en) 2008-12-11 2009-12-08 Synthesis of HIV integrase inhibitors carbamoylpyridone and intermediates
SG2011035102A SG171308A1 (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
AU2009325128A AU2009325128B2 (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US13/128,992 US8624023B2 (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US14/096,191 US8754214B2 (en) 2008-12-11 2013-12-04 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US14/272,823 US9242986B2 (en) 2008-12-11 2014-05-08 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
AU2014277831A AU2014277831C1 (en) 2008-12-11 2014-12-19 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
US14/936,987 US9365587B2 (en) 2008-12-11 2015-11-10 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19363408P 2008-12-11 2008-12-11
US61/193,634 2008-12-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/128,992 A-371-Of-International US8624023B2 (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US14/096,191 Division US8754214B2 (en) 2008-12-11 2013-12-04 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates

Publications (1)

Publication Number Publication Date
WO2010068253A1 true WO2010068253A1 (en) 2010-06-17

Family

ID=42242992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/006422 WO2010068253A1 (en) 2008-12-11 2009-12-08 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates

Country Status (15)

Country Link
US (4) US8624023B2 (en)
EP (2) EP3210603A1 (en)
JP (3) JP5086478B2 (en)
KR (2) KR101733625B1 (en)
CN (1) CN102245182B (en)
AU (1) AU2009325128B2 (en)
BR (1) BRPI0923217A2 (en)
CA (2) CA2955957A1 (en)
ES (1) ES2641765T3 (en)
HK (1) HK1243626A1 (en)
MX (2) MX2011006241A (en)
RU (2) RU2527451C2 (en)
SG (1) SG171308A1 (en)
TW (1) TWI483947B (en)
WO (1) WO2010068253A1 (en)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094150A1 (en) 2010-01-27 2011-08-04 Glaxosmithkline Llc Antiviral therapy
WO2012018065A1 (en) * 2010-08-05 2012-02-09 塩野義製薬株式会社 Process for preparing compound having hiv integrase inhibitory activity
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2013038407A1 (en) 2011-09-14 2013-03-21 Mapi Pharma Ltd. Amorphous form of dolutegravir
US8552187B2 (en) 2008-12-11 2013-10-08 Shionogi & Co., Ltd. Processes and intermediates for carbamoylpyridone HIV integrase inhibitors
US8580967B2 (en) 2008-07-25 2013-11-12 Shionogi & Co., Ltd. Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate and processes for the preparation thereof
US8624023B2 (en) 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014125124A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
US8865907B2 (en) 2009-03-26 2014-10-21 Shionogi & Co., Ltd. Method of producing pyrone and pyridone derivatives
US8889877B2 (en) 2010-03-23 2014-11-18 Viiv Healthcare Company Processes for preparing pyridinone carboxylic acid aldehydes
WO2015009927A1 (en) 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) * 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
WO2015092752A1 (en) * 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015118460A1 (en) 2014-02-07 2015-08-13 Mylan Laboratories Ltd. Crystalline forms of dolutegravir sodium
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
WO2015110897A3 (en) * 2014-01-21 2015-12-03 Laurus Labs Private Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
EP2980091A1 (en) 2014-07-29 2016-02-03 LEK Pharmaceuticals d.d. Novel hydrates of dolutegravir sodium
WO2016016279A1 (en) * 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
WO2016127965A1 (en) 2015-02-13 2016-08-18 Zentiva, K.S. Solid forms of dolutegravir salts and a method of their preparation
WO2017020878A1 (en) 2015-08-04 2017-02-09 Zentiva, K. S. Solid forms of amorphous dolutegravir
WO2017029642A2 (en) 2015-08-19 2017-02-23 Laurus Labs Private Limited Novel polymorphs of dolutegravir and salts thereof
WO2017046131A1 (en) * 2015-09-15 2017-03-23 Ratiopharm Gmbh Processes for preparing solid state forms of dolutegravir sodium
CN106866701A (en) * 2014-03-19 2017-06-20 杭州普晒医药科技有限公司 Crystal formation of De Luogewei sodium salts and preparation method thereof
US9682084B2 (en) 2014-06-20 2017-06-20 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US9732092B2 (en) 2012-12-21 2017-08-15 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
WO2018109786A1 (en) * 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
EP3363802A1 (en) 2017-02-16 2018-08-22 Sandoz AG Crystalline form of cabotegravir sodium
WO2018149608A1 (en) 2017-02-16 2018-08-23 Sandoz Ag Crystalline forms of cabotegravir sodium
WO2019048808A1 (en) 2017-09-07 2019-03-14 Cipla Limited New polymorphs of dolutegravir sodium
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
WO2019070059A1 (en) 2017-10-06 2019-04-11 塩野義製薬株式会社 Method for stereoselectively producing substituted polycyclic pyridone derivative
US10385067B2 (en) 2014-06-20 2019-08-20 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
US10442769B2 (en) 2013-07-04 2019-10-15 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
US10456395B2 (en) 2013-07-12 2019-10-29 Gilead Sciences, Inc. Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
WO2020221294A1 (en) * 2019-04-30 2020-11-05 上海拓界生物医药科技有限公司 Bridge ring-3,4-dihydro-pyrido[1,2-a]pyrazine-1,8-dione compound and pharmaceutical use thereof
US11084832B2 (en) 2019-03-22 2021-08-10 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
US11224597B2 (en) 2010-09-16 2022-01-18 Viiv Healthcare Company Pharmaceutical compositions
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CN114426540A (en) * 2020-10-29 2022-05-03 上海拓界生物医药科技有限公司 Pyrido [1,2-a ] pyrazine-1, 8-diketone prodrug derivatives, preparation method and application thereof
WO2022107755A1 (en) 2020-11-17 2022-05-27 塩野義製薬株式会社 Novel acridinium salt and method for producing same
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
US11697652B2 (en) 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
US12024528B2 (en) 2022-04-06 2024-07-02 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US12122776B2 (en) 2023-05-12 2024-10-22 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (en) 2011-12-16 2019-03-13 Glaxosmithkline Llc Derivatives of betulin
SG10201704467SA (en) * 2012-12-14 2017-06-29 Glaxosmithkline Llc Pharmaceutical compositions
WO2014200880A1 (en) * 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
PT3252058T (en) 2013-07-12 2021-03-09 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
JP2017528497A (en) 2014-09-26 2017-09-28 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Long-acting pharmaceutical composition
TWI738321B (en) 2014-12-23 2021-09-01 美商基利科學股份有限公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
ES2837383T3 (en) 2015-04-02 2021-06-30 Gilead Sciences Inc Polycyclic carbamoylpyridone compounds and their pharmaceutical use
WO2017109649A1 (en) 2015-12-21 2017-06-29 Lupin Limited Process for the preparation of hiv integrase inhibitors
WO2018020380A1 (en) 2016-07-25 2018-02-01 Lupin Limited Enzymatic process for the preparation of (r)-3-aminobutan-1-ol, useful in preparation of dolutegravir
CN108250215B (en) * 2016-12-28 2022-04-19 华创合成制药股份有限公司 Novel anti-HIV medicine, preparation method and application thereof
CN109879843B (en) * 2019-02-11 2020-08-28 常州制药厂有限公司 Barosavir intermediate, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919351B2 (en) * 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
WO2006116764A1 (en) 2005-04-28 2006-11-02 Smithkline Beecham Corporation Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524149A (en) 1982-03-15 1985-06-18 Sterling Drug Inc. 5-Alkanoyl-6-alkyl-2(1H)-pyridinones, their preparation and their cardiotonic use
US4769380A (en) 1983-04-29 1988-09-06 Merrell Dow Pharmaceuticals Inc. Cardiotonic 5-benzoyl-1,2-dihydro-2-oxo-3-pyridinecarboxylates
US4735964A (en) 1984-08-16 1988-04-05 G. D. Searle & Co. Kojic acid ether-ester derivatives
US4603144A (en) 1984-08-16 1986-07-29 G. D. Searle & Co. Kojic acid ether-ester derivatives
US4812474A (en) 1984-08-16 1989-03-14 G. D. Searle & Co. Kojic acid ether-ester derivatives
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
GB2280435A (en) 1993-07-29 1995-02-01 Merck & Co Inc Anti-viral agent
RU2167877C2 (en) * 1995-05-31 2001-05-27 Эйсай Ко., Лтд. Derivatives of condensed polycyclic heterocyclic compounds and method of their synthesis
DE59611243D1 (en) 1995-09-29 2005-08-11 Novartis Ag hydroxypyridinones
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
JP2005505525A (en) 2001-08-02 2005-02-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Gonadotropin-releasing hormone receptor antagonist and related methods
US6426418B1 (en) 2001-11-02 2002-07-30 Apotex, Inc. Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide
CA2379370A1 (en) 2002-03-28 2003-09-28 Apotex Inc. Carboxylic acid derivatives of 3-hydroxy-4-oxo-1,4-dihydropyridine as iron chelators
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
JP4733986B2 (en) * 2002-12-27 2011-07-27 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Tetrahydro-4H-pyrido [1,2-a] pyrimidines and related compounds useful as HIV integrase inhibitors
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP2006232849A (en) * 2003-08-13 2006-09-07 Japan Tobacco Inc Nitrogenous fused-ring compound and use thereof as hiv integrase inhibitor
DE10349500A1 (en) 2003-10-23 2005-06-02 Bayer Cropscience Ag A process for producing 2-dihaloacyl-3-amino-acrylic acid esters and 3-dihalomethyl-pyrazole-4-carboxylic acid esters
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
CA2557785A1 (en) 2004-03-09 2005-10-06 Merck & Co. Inc. Hiv integrase inhibitors
AU2005249363A1 (en) 2004-04-14 2005-12-15 Zhenhong R. Cai Phosphonate analogs of HIV integrase inhibitor compounds
RU2266906C1 (en) * 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Anellated carbamoyl azaheterocycles, methods for their preparing (variants), pharmaceutical composition, focused library
EP1790638B1 (en) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
CA2488034C (en) 2004-11-19 2009-10-06 Apotex Inc. Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
CA2634499A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
ATE516026T1 (en) 2005-02-21 2011-07-15 Shionogi & Co BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE WITH HIV INTEGRASE INHIBITING EFFECT
AR057023A1 (en) 2005-05-16 2007-11-14 Gilead Sciences Inc HETEROCICLICAL COMPOUNDS WITH HIV-INTEGRASA INHIBITING PROPERTIES
JP2006342115A (en) 2005-06-10 2006-12-21 Shionogi & Co Ltd Polycyclic compound having hiv integrase inhibition activity
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
CN101981047A (en) * 2008-01-03 2011-02-23 Viro化学制药公司 Novel lupane derivatives
AU2009214779A1 (en) * 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
KR101695807B1 (en) 2008-07-25 2017-01-13 비이브 헬쓰케어 컴퍼니 Chemical compounds
PT2320908E (en) 2008-07-25 2014-03-06 Shionogi & Co Dolutegravir prodrugs
ES2449752T3 (en) 2008-07-25 2014-03-21 Viiv Healthcare Company Process for the preparation of a pyrido [1,2-a] pyrrolo [1 ', 2': 3,4] imidazo [1,2-d] pyrazine-8-carboxamide derivative
MX2011006241A (en) 2008-12-11 2011-06-28 Shionogi & Co Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates.
ES2964383T3 (en) 2008-12-11 2024-04-05 Viiv Healthcare Co Processes and intermediates for carbamoylpyridone HIV integrase inhibitors
TWI518084B (en) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 Process for pyrone and pyridone derivatives
TWI582097B (en) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 Process for preparing carbamoylpyridone derivatives and intermediates
CN103154004B (en) 2010-08-05 2016-07-06 盐野义制药株式会社 There is the manufacture method of the compound of hiv integrase inhibitory activity
US8361208B2 (en) 2010-10-20 2013-01-29 Cameron International Corporation Separator helix

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919351B2 (en) * 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
WO2006116764A1 (en) 2005-04-28 2006-11-02 Smithkline Beecham Corporation Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"The Japanese Pharmacopoeia"
J. ALBANEZE-WALKER ET AL., ORGANIC LETTERS, vol. 6, no. 13, 2004, pages 2097 - 2100
J.R. MARTINELLI ET AL., ORGANIC LETTERS, vol. 8, no. 21, 2006, pages 4843 - 4846

Cited By (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8765965B2 (en) 2008-07-25 2014-07-01 Shionogi & Co., Ltd. 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid of the formula P-6 and/or methyl 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate of the formula P-7
US8981129B2 (en) 2008-07-25 2015-03-17 Shionogi & Co., Ltd. 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one of the formula P-3 and/or 2-[(E)-2-phenylethenyl]-3-[(phenylmethyl)oxy]-4H-Pyran-4-one of the formula P-4
US8940912B2 (en) 2008-07-25 2015-01-27 Viiv Healthcare Company 4-oxo-3-[(phenylmethyl)oxy]-4H-pyran-2-carboxylic acid
US9707246B2 (en) 2008-07-25 2017-07-18 Shionogi & Co., Ltd. Substituted (3S,11AR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11A-hexahydro[1,3]oxazolo[3,2-A]pyrido[1,2-D]pyrazine-8-carboxamides as HIV agents
US9012650B2 (en) 2008-07-25 2015-04-21 Shionogi & Co., Ltd. Substituted (3S, 11aR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides of formula (I) useful as HIV agents
US8580967B2 (en) 2008-07-25 2013-11-12 Shionogi & Co., Ltd. Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate and processes for the preparation thereof
US9133216B2 (en) 2008-07-25 2015-09-15 Shionogi & Co., Ltd. (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenymethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10
US8669362B2 (en) 2008-12-11 2014-03-11 Shiongi & Co., Ltd. Processes and Intermediates for carbamoylpyridone HIV integrase inhibitors
US9242986B2 (en) 2008-12-11 2016-01-26 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US9365587B2 (en) 2008-12-11 2016-06-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8754214B2 (en) 2008-12-11 2014-06-17 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8624023B2 (en) 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8552187B2 (en) 2008-12-11 2013-10-08 Shionogi & Co., Ltd. Processes and intermediates for carbamoylpyridone HIV integrase inhibitors
US8865907B2 (en) 2009-03-26 2014-10-21 Shionogi & Co., Ltd. Method of producing pyrone and pyridone derivatives
US9260453B2 (en) 2009-03-26 2016-02-16 Shionogi & Co., Ltd. Method for producing pyrone and pyridone derivatives
US9505783B2 (en) 2009-03-26 2016-11-29 Shionogi & Co., Ltd. Method of producing pyrone and pyridone derivatives
EP2932970A1 (en) 2010-01-27 2015-10-21 VIIV Healthcare Company Antiviral therapy
KR20180078358A (en) * 2010-01-27 2018-07-09 비이브 헬쓰케어 컴퍼니 Antibiral therapy
KR101964923B1 (en) 2010-01-27 2019-04-02 비이브 헬쓰케어 컴퍼니 Antibiral therapy
EP4316599A2 (en) 2010-01-27 2024-02-07 VIIV Healthcare Company Antiviral therapy
EP3494972A1 (en) 2010-01-27 2019-06-12 VIIV Healthcare Company Combinations of dolutegravir and lamivudine for the treaetment of hiv infection
US11234985B2 (en) 2010-01-27 2022-02-01 Viiv Healthcare Company Antiviral therapy
WO2011094150A1 (en) 2010-01-27 2011-08-04 Glaxosmithkline Llc Antiviral therapy
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
US10426780B2 (en) 2010-01-27 2019-10-01 Viiv Healthcare Company Antiviral therapy
US9120817B2 (en) 2010-03-23 2015-09-01 Viiv Healthcare Company Process for preparing (4R,12aS)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′ ,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid
US8889877B2 (en) 2010-03-23 2014-11-18 Viiv Healthcare Company Processes for preparing pyridinone carboxylic acid aldehydes
US9938296B2 (en) 2010-03-23 2018-04-10 Viiv Healthcare Company Process for preparing (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
US10647728B2 (en) 2010-03-23 2020-05-12 Viiv Healthcare Company Process for preparing (3S,11aR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-Hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid
US10654870B2 (en) 2010-03-23 2020-05-19 Viiv Healthcare Company Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives
US9643981B2 (en) 2010-03-23 2017-05-09 Viiv Healthcare Company Process for preparing (4R,12aS)-N-(2,4-difluorobenzyl)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
US10654871B2 (en) 2010-03-23 2020-05-19 Viiv Healthcare Company Process for preparing (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
US10233196B2 (en) 2010-03-23 2019-03-19 Viiv Healthcare Company Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives
US10174051B2 (en) 2010-03-23 2019-01-08 Viiv Healthcare Company Substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives
CN106046022B (en) * 2010-08-05 2018-06-19 盐野义制药株式会社 The manufacturing method of compound with hiv integrase inhibitory activity
CN106083891A (en) * 2010-08-05 2016-11-09 盐野义制药株式会社 There is the manufacture method of the compound of hiv integrase inhibitory activity
WO2012018065A1 (en) * 2010-08-05 2012-02-09 塩野義製薬株式会社 Process for preparing compound having hiv integrase inhibitory activity
US10125147B2 (en) 2010-08-05 2018-11-13 Shionogi & Co., Ltd. Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate
EP3456721A2 (en) 2010-08-05 2019-03-20 Shionogi & Co., Ltd Method of producing compounds having hiv integrase inhivitory activity
JP5636054B2 (en) * 2010-08-05 2014-12-03 塩野義製薬株式会社 Method for producing compound having HIV integrase inhibitory activity
JPWO2012018065A1 (en) * 2010-08-05 2013-10-03 塩野義製薬株式会社 Method for producing compound having HIV integrase inhibitory activity
CN106046022A (en) * 2010-08-05 2016-10-26 盐野义制药株式会社 Process for preparing compound having HIV integrase inhibitory activity
TWI510451B (en) * 2010-08-05 2015-12-01 Shionogi & Co Manufacturing method for compounds having hiv integrase inhibitory activities
US10125146B2 (en) 2010-08-05 2018-11-13 Shionogi & Co., Ltd. Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate
US9321789B2 (en) 2010-08-05 2016-04-26 Shinogi & Co., Ltd. Methods of producing substituted (4R,12AS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-B][1,3]oxazine-9-carboxamides
EP3127908A2 (en) 2010-08-05 2017-02-08 Shionogi & Co., Ltd Process for preparing compound having hiv integrase inhibitory activity
US9650394B2 (en) 2010-08-05 2017-05-16 Shionogi & Co., Ltd. Methods of producing substituted (3S,11aR)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-Hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides
US10000508B2 (en) 2010-08-05 2018-06-19 Shionogi & Co., Ltd Crystalline dimethyl 3-(benzyloxy)-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylate
US9969750B2 (en) 2010-08-05 2018-05-15 Shionogi And Co., Ltd. Method of producing (3S,11aR)-6,8-dihalo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-diones
CN106083891B (en) * 2010-08-05 2018-03-23 盐野义制药株式会社 The manufacture method of compound with hiv integrase inhibitory activity
US9802959B2 (en) 2010-08-05 2017-10-31 Shionogi & Co., Ltd. Method of producing (4R,12aS)-7,9-dihalo-4-methyl-3,4,12,12a-tetrahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-6,8-diones
US11224597B2 (en) 2010-09-16 2022-01-18 Viiv Healthcare Company Pharmaceutical compositions
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2013038407A1 (en) 2011-09-14 2013-03-21 Mapi Pharma Ltd. Amorphous form of dolutegravir
US9206197B2 (en) 2011-09-14 2015-12-08 Mapi Pharma Ltd. Amorphous form of dolutegravir
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
US9732092B2 (en) 2012-12-21 2017-08-15 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
CN111303152A (en) * 2012-12-21 2020-06-19 吉利德科学公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN111303152B (en) * 2012-12-21 2023-04-11 吉利德科学公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US10689399B2 (en) 2012-12-21 2020-06-23 Gilead Sciences, Inc. Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections
US11548901B2 (en) 2012-12-21 2023-01-10 Gilead Sciences, Inc. Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections
US10035809B2 (en) 2012-12-21 2018-07-31 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014125124A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
US9480655B2 (en) * 2013-02-18 2016-11-01 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
US10442769B2 (en) 2013-07-04 2019-10-15 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
US11213523B2 (en) 2013-07-12 2022-01-04 Gilead Sciences, Inc. Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
US10456395B2 (en) 2013-07-12 2019-10-29 Gilead Sciences, Inc. Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections
US11883397B2 (en) 2013-07-12 2024-01-30 Gilead Sciences, Inc. Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
WO2015009927A1 (en) 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
US9856270B2 (en) 2013-07-17 2018-01-02 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) * 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015092752A1 (en) * 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015110897A3 (en) * 2014-01-21 2015-12-03 Laurus Labs Private Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
US10087193B2 (en) 2014-02-07 2018-10-02 Mylan Laboratories Limited Crystalline forms of dolutegravir sodium
WO2015118460A1 (en) 2014-02-07 2015-08-13 Mylan Laboratories Ltd. Crystalline forms of dolutegravir sodium
AU2015215630B2 (en) * 2014-02-07 2018-08-16 Mylan Laboratories Ltd. Crystalline forms of dolutegravir sodium
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
CN106866701A (en) * 2014-03-19 2017-06-20 杭州普晒医药科技有限公司 Crystal formation of De Luogewei sodium salts and preparation method thereof
CN106866701B (en) * 2014-03-19 2019-03-19 杭州普晒医药科技有限公司 The crystal form and preparation method thereof of De Luogewei sodium salt
CN107056813A (en) * 2014-03-19 2017-08-18 杭州普晒医药科技有限公司 Crystal formation of De Luogewei sodium salts and preparation method thereof
CN107056813B (en) * 2014-03-19 2019-07-30 杭州普晒医药科技有限公司 The crystal form and preparation method thereof of De Luogewei sodium salt
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US9682084B2 (en) 2014-06-20 2017-06-20 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10098886B2 (en) 2014-06-20 2018-10-16 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13A- octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide
US10975096B2 (en) 2014-06-20 2021-04-13 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US11202780B2 (en) 2014-06-20 2021-12-21 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10385067B2 (en) 2014-06-20 2019-08-20 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
WO2016016279A1 (en) * 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
EP2980091A1 (en) 2014-07-29 2016-02-03 LEK Pharmaceuticals d.d. Novel hydrates of dolutegravir sodium
US10189860B2 (en) 2014-07-29 2019-01-29 Lek Pharmaceuticals D.D. Hydrates of dolutegravir sodium
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
WO2016102078A1 (en) * 2014-12-24 2016-06-30 Ratiopharm Gmbh Solid state forms of dolutegravir sodium
US10335394B2 (en) 2015-01-16 2019-07-02 Lek Pharmaceuticals D.D. Processes for preparing dolutegravir and cabotegravir and analogues thereof
WO2016113372A1 (en) 2015-01-16 2016-07-21 Lek Pharmaceuticals D.D. Processes for preparing dolutegravir and cabotegravir and analogues thereof
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
WO2016127965A1 (en) 2015-02-13 2016-08-18 Zentiva, K.S. Solid forms of dolutegravir salts and a method of their preparation
WO2017020878A1 (en) 2015-08-04 2017-02-09 Zentiva, K. S. Solid forms of amorphous dolutegravir
WO2017029642A2 (en) 2015-08-19 2017-02-23 Laurus Labs Private Limited Novel polymorphs of dolutegravir and salts thereof
US10647729B1 (en) 2015-08-19 2020-05-12 Laurus Labs Limited Polymorphs of dolutegravir and salts thereof
WO2017029642A3 (en) * 2015-08-19 2017-04-06 Laurus Labs Private Limited Novel polymorphs of dolutegravir and salts thereof
US10654872B1 (en) 2015-08-19 2020-05-19 Laurus Labs Limited Polymorphs of dolutegravir and salts thereof
US10597404B2 (en) 2015-08-19 2020-03-24 Laurus Labs Ltd. Polymorphs of dolutegravir and salts thereof
WO2017046131A1 (en) * 2015-09-15 2017-03-23 Ratiopharm Gmbh Processes for preparing solid state forms of dolutegravir sodium
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
WO2018109786A1 (en) * 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
US11040986B2 (en) 2017-02-16 2021-06-22 Sandoz Ag Crystalline forms of cabotegravir sodium
EP3363802A1 (en) 2017-02-16 2018-08-22 Sandoz AG Crystalline form of cabotegravir sodium
WO2018149608A1 (en) 2017-02-16 2018-08-23 Sandoz Ag Crystalline forms of cabotegravir sodium
AU2022200513B2 (en) * 2017-02-16 2023-11-02 ViiV Healthcare UK (No.3) Limited Crystalline forms of cabotegravir sodium
WO2019048808A1 (en) 2017-09-07 2019-03-14 Cipla Limited New polymorphs of dolutegravir sodium
WO2019070059A1 (en) 2017-10-06 2019-04-11 塩野義製薬株式会社 Method for stereoselectively producing substituted polycyclic pyridone derivative
KR20200066644A (en) 2017-10-06 2020-06-10 시오노기세야쿠 가부시키가이샤 Method for stereoselective production of substituted polycyclic pyridone derivatives
US11286262B2 (en) 2017-10-06 2022-03-29 Shionogi & Co., Ltd. Stereoselective process for preparing substituted polycyclic pyridone derivatives
US11084832B2 (en) 2019-03-22 2021-08-10 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
US11548902B1 (en) 2019-03-22 2023-01-10 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CN113795491A (en) * 2019-04-30 2021-12-14 上海拓界生物医药科技有限公司 Bridged ring-3, 4-dihydro-pyrido [1,2-a ] pyrazine-1, 8-dione compound and pharmaceutical use thereof
WO2020221294A1 (en) * 2019-04-30 2020-11-05 上海拓界生物医药科技有限公司 Bridge ring-3,4-dihydro-pyrido[1,2-a]pyrazine-1,8-dione compound and pharmaceutical use thereof
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
US11697652B2 (en) 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
CN114426540B (en) * 2020-10-29 2024-04-26 上海拓界生物医药科技有限公司 Pyrido [1,2-a ] pyrazine-1, 8-dione prodrug derivatives, preparation method and application thereof
CN114426540A (en) * 2020-10-29 2022-05-03 上海拓界生物医药科技有限公司 Pyrido [1,2-a ] pyrazine-1, 8-diketone prodrug derivatives, preparation method and application thereof
WO2022107755A1 (en) 2020-11-17 2022-05-27 塩野義製薬株式会社 Novel acridinium salt and method for producing same
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
US11897892B2 (en) 2021-01-19 2024-02-13 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
US12024528B2 (en) 2022-04-06 2024-07-02 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US12054496B2 (en) 2022-04-06 2024-08-06 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US12122776B2 (en) 2023-05-12 2024-10-22 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof

Also Published As

Publication number Publication date
CA2955957A1 (en) 2010-06-17
JP6130891B2 (en) 2017-05-17
AU2009325128A1 (en) 2011-07-07
CN102245182A (en) 2011-11-16
CN102245182B (en) 2014-07-23
KR101733625B1 (en) 2017-05-10
JP2012511573A (en) 2012-05-24
US9242986B2 (en) 2016-01-26
SG171308A1 (en) 2011-07-28
US8624023B2 (en) 2014-01-07
EP2376080A1 (en) 2011-10-19
KR20170038116A (en) 2017-04-05
JP2016041727A (en) 2016-03-31
MX351942B (en) 2017-11-03
JP2012131791A (en) 2012-07-12
US20140243521A1 (en) 2014-08-28
AU2009325128B2 (en) 2015-01-29
US20110282055A1 (en) 2011-11-17
CA2744019C (en) 2017-03-14
US9365587B2 (en) 2016-06-14
RU2013153004A (en) 2015-06-10
US8754214B2 (en) 2014-06-17
US20140094605A1 (en) 2014-04-03
TWI483947B (en) 2015-05-11
EP2376080B1 (en) 2017-09-13
RU2011121785A (en) 2013-01-20
HK1243626A1 (en) 2018-07-20
RU2527451C2 (en) 2014-08-27
EP2376080A4 (en) 2012-07-11
KR101847887B1 (en) 2018-04-11
BRPI0923217A2 (en) 2017-05-23
CA2744019A1 (en) 2010-06-17
MX2011006241A (en) 2011-06-28
RU2638923C2 (en) 2017-12-19
ES2641765T3 (en) 2017-11-13
JP5086478B2 (en) 2012-11-28
KR20110094336A (en) 2011-08-23
TW201030010A (en) 2010-08-16
US20160060274A1 (en) 2016-03-03
EP3210603A1 (en) 2017-08-30
JP5848595B2 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
US9365587B2 (en) Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
EP2376453B1 (en) Intermediates for carbamoylpyridone hiv integrase inhibitors
AU2014277831B2 (en) Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980149697.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09832226

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1942/KOLNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2744019

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009325128

Country of ref document: AU

Ref document number: MX/A/2011/006241

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011540689

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009325128

Country of ref document: AU

Date of ref document: 20091208

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117016066

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2009832226

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011121785

Country of ref document: RU

Ref document number: 2009832226

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13128992

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI0923217

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI0923217

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110608